PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kosaka, T; Takaori, K; Izumiya, A; Hirai, D; Koizumi, M; Yamamoto, S; Mii, A; Shimizu, A; Nakamura, K; Araki, N; Seta, K				Kosaka, Tatsuaki; Takaori, Koji; Izumiya, Azusa; Hirai, Daisuke; Koizumi, Mitsuteru; Yamamoto, Shinya; Mii, Akiko; Shimizu, Akira; Nakamura, Kiyonao; Araki, Norio; Seta, Koichi			Radiation Nephropathy Complicated by Tubulointerstitial Nephritis with Predominantly Lymphocyte and Plasma Cell Infiltration	INTERNAL MEDICINE			English	Article						radiation nephropathy; thrombotic microangiopathy; tubulointerstitial nephritis; contrast-enhanced computed tomography	CHEMOTHERAPY; RADIOTHERAPY	A 64-year-old Japanese woman presented with gross hematuria and was diagnosed with stage IVB cervical cancer. Renal dysfunction was observed following chemoradiation therapy, and a renal biopsy revealed renal thrombotic microangiopathy (TMA) and tubulointerstitial nephritis (TIN), which are atypical features of radiation nephropathy. Contrast-enhanced computed tomography revealed wedge-shaped areas of high contrast, consistent with areas of high radiation dose in the kidneys, thus leading to the diagnosis of radiation nephropathy. This case underscores the importance of integrating clinical, pathological, and radiological findings for the diagnosis of radiation nephropathy, atypical renal biopsy findings, and a combination of TIN and renal TMA.	[Kosaka, Tatsuaki; Takaori, Koji; Izumiya, Azusa; Hirai, Daisuke; Koizumi, Mitsuteru; Seta, Koichi] Natl Hosp Org, Dept Nephrol, Kyoto Med Ctr, Kyoto, Japan; [Yamamoto, Shinya] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan; [Mii, Akiko] Nippon Med Sch, Dept Endocrinol Metab & Nephrol, Tokyo, Japan; [Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo, Japan; [Nakamura, Kiyonao] Kyoto City Hosp, Dept Radiat Oncol, Kyoto, Japan; [Araki, Norio] Natl Hosp Org, Dept Radiat Oncol, Kyoto Med Ctr, Kyoto, Japan	Kyoto University; Nippon Medical School; Nippon Medical School; Kyoto City Hospital	Seta, K (corresponding author), Natl Hosp Org, Dept Nephrol, Kyoto Med Ctr, Kyoto, Japan.	kjtakaori@gmail.com		Kosaka, Tatsuaki/0000-0003-1140-3561				BERGSTEIN J, 1986, TRANSPLANTATION, V41, P63, DOI 10.1097/00007890-198601000-00013; Burton JO, 2014, KIDNEY INT, V86, P1063, DOI 10.1038/ki.2014.127; Capps GW, 1997, RADIOGRAPHICS, V17, P1455, DOI 10.1148/radiographics.17.6.9397458; Cheng JC, 2008, INT J RADIAT ONCOL, V71, P1436, DOI 10.1016/j.ijrobp.2007.12.009; Cohen EP, 2000, KIDNEY INT, V58, P903, DOI 10.1046/j.1523-1755.2000.00241.x; Cohen EP, 2003, SEMIN NEPHROL, V23, P486, DOI 10.1016/S0270-9295(03)00093-7; Cohen EP, 2003, INT J RADIAT ONCOL, V55, P190, DOI 10.1016/S0360-3016(02)03793-8; DHALIWAL RS, 1980, J PEDIATR-US, V96, P68, DOI 10.1016/S0022-3476(80)80331-3; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Ferenbach DA, 2015, NAT REV NEPHROL, V11, P264, DOI 10.1038/nrneph.2015.3; François H, 2016, NAT REV NEPHROL, V12, P82, DOI 10.1038/nrneph.2015.174; Harkenrider MM, 2015, INT J RADIAT ONCOL, V92, P921, DOI 10.1016/j.ijrobp.2015.03.010; JENNETTE JC, 1983, UROLOGY, V22, P631, DOI 10.1016/0090-4295(83)90313-8; Kala J, 2019, Journal of Onco-Nephrology, V3, P160, DOI [10.1177/2399369319865271, DOI 10.1177/2399369319865271, 10.1177/2399369319865271]; Klaus R, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01764-y; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Latcha S, 2016, CLIN J AM SOC NEPHRO, V11, P1173, DOI 10.2215/CJN.08070715; Li SP, 2023, J COSMOL ASTROPART P, DOI [10.1088/1475-7516/2023/09/009, 10.1088/1475-7516/2023/05/008]; Malyszko J, 2017, NEPHROL DIAL TRANSPL, V32, P924, DOI 10.1093/ndt/gfw338; Moinuddin I, 2015, CASE REP MED, V2015, DOI 10.1155/2015/250530; Najafian B, 2015, AM J KIDNEY DIS, V66, pE39, DOI 10.1053/j.ajkd.2015.08.009; Saeki T, 2014, KIDNEY INT, V85, P251, DOI 10.1038/ki.2013.393; Sato T, 2018, TOHOKU J EXP MED, V245, P149, DOI 10.1620/tjem.245.149; Schieda N, 2013, ACTA RADIOL OPEN, V2, DOI 10.1177/2047981613501305; Skinner HD, 2010, J GASTROINTEST ONCOL, V1, P2, DOI 10.3978/j.issn.2078-6891.2010.007; Stoffel MP, 2001, NEPHROL DIAL TRANSPL, V16, P1082, DOI 10.1093/ndt/16.5.1082; Takahashi N, 2017, J AM SOC NEPHROL, V28, P3688, DOI 10.1681/ASN.2016101074; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Yoshimura J, 2007, INTERNAL MED, V46, P1861, DOI 10.2169/internalmedicine.46.0103	29	0	1	3	3	JAPAN SOC INTERNAL MEDICINE	TOKYO	34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN	0918-2918	1349-7235		INTERNAL MED	Intern. Med.		2025	64	11					1696	1705		10.2169/internalmedicine.4265-24	http://dx.doi.org/10.2169/internalmedicine.4265-24			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3UF9X	39496448	gold, Green Submitted			2025-09-11	WOS:001509138400013
J	Terazawa, T; Kato, T; Goto, M; Ohta, K; Satake, H; Noura, S; Kagawa, Y; Kawakami, H; Hasegawa, H; Yanagihara, K; Shingai, T; Nakata, K; Kotaka, M; Hiraki, M; Konishi, K; Nakae, S; Sakai, D; Kurokawa, Y; Shimokawa, T; Tsujinaka, T; Satoh, T				Terazawa, Tetsuji; Kato, Takeshi; Goto, Masahiro; Ohta, Katsuya; Satake, Hironaga; Noura, Shingo; Kagawa, Yoshinori; Kawakami, Hisato; Hasegawa, Hiroko; Yanagihara, Kazuhiro; Shingai, Tatsushi; Nakata, Ken; Kotaka, Masahito; Hiraki, Masayuki; Konishi, Ken; Nakae, Shiro; Sakai, Daisuke; Kurokawa, Yukinori; Shimokawa, Toshio; Tsujinaka, Toshimasa; Satoh, Taroh			The Phase II Study of Panitumumab in Chemotherapy-Naive Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results	ONCOLOGIST			English	Article; Early Access						colorectal cancer; frail patient; elderly patients; panitumumab	EARLY TUMOR SHRINKAGE; SINGLE-AGENT PANITUMUMAB; OPEN-LABEL; BEVACIZUMAB; DEPTH; TRIAL; LOCATION	Background We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis. Methods Patients aged >= 65 years and considered unsuitable for intensive chemotherapy or aged >= 76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs). Results Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043]. Conclusion Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528). This article presents a survival analysis of the phase II OGSG1602 trial on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer.	[Terazawa, Tetsuji; Goto, Masahiro] Osaka Med & Pharmaceut Univ, Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan; [Kato, Takeshi] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol Surg, Higashiosaka, Osaka, Japan; [Ohta, Katsuya] Higashiosaka City Med Ctr, Dept Gastroenterol Surg, Osaka, Japan; [Satake, Hironaga] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan; [Noura, Shingo] Osaka Rosai Hosp, Dept Gastroenterol Surg, Sakai, Osaka, Japan; [Noura, Shingo] Toyonaka City Hosp, Dept Gastroenterol Surg, Toyonaka, Osaka, Japan; [Kagawa, Yoshinori] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan; [Kawakami, Hisato] Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan; [Hasegawa, Hiroko] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan; [Yanagihara, Kazuhiro] Kansai Elect Power Hosp, Dept Med Oncol, Osaka, Japan; [Shingai, Tatsushi] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan; [Nakata, Ken] Sakai City Med Ctr, Dept Surg, Sakai, Osaka, Japan; [Kotaka, Masahito] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan; [Hiraki, Masayuki] Itami City Hosp, Dept Surg, Itami, Hyogo, Japan; [Konishi, Ken] Hyogo Prefectural Nishinomiya Hosp, Dept Surg, Nishinomiya, Hyogo, Japan; [Nakae, Shiro] Mimihara Gen Hosp, Dept Med Oncol, Sakai, Osaka, Japan; [Sakai, Daisuke; Satoh, Taroh] Osaka Univ, Dept Frontier Sci Canc & Chemotherapy, Grad Sch Med, Suita, Osaka, Japan; [Kurokawa, Yukinori] Osaka Univ, Dept Gastroenterol Surg, Grad Sch Med, Osaka, Japan; [Shimokawa, Toshio] Wakayama Med Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka, Japan; [Tsujinaka, Toshimasa] Izumi City Gen Hosp, Canc Ctr, Izumi, Japan	Osaka Medical & Pharmaceutical University; Osaka National Hospital; Kobe City Medical Center General Hospital; Osaka Rosai Hospital; Kansai Rosai Hospital; Osaka National Hospital; University of Osaka; University of Osaka	Kato, T (corresponding author), Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol Surg, Chuo Ku, 2-1-14 Hoenzaka, Osaka 5400006, Japan.	ken-kato@momo.so-net.ne.jp	; Kawakami, Hisato/L-6845-2019; Satoh, Taroh/AAF-5193-2021; Satake, Hironaga/G-6243-2013	Kawakami, Hisato/0000-0002-3280-4850; Hiraki, Masayuki/0000-0001-6445-7390; 	Osaka Gastrointestinal Cancer Chemotherapy Study Group - Takeda Pharmaceutical Company Limited	Osaka Gastrointestinal Cancer Chemotherapy Study Group - Takeda Pharmaceutical Company Limited	This study was supported by Osaka Gastrointestinal Cancer Chemotherapy Study Group and funded by Takeda Pharmaceutical Company Limited.	Aarts MJ, 2010, EUR J CANCER, V46, P2681, DOI 10.1016/j.ejca.2010.04.026; Bekaii-Saab T, 2014, J NATL COMPR CANC NE, V12, P299, DOI 10.6004/jnccn.2014.0027; Boeckx N, 2017, ANN ONCOL, V28, P1862, DOI 10.1093/annonc/mdx119; Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015; Cremolini C, 2015, ANN ONCOL, V26, P1188, DOI 10.1093/annonc/mdv112; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; Froelich MF, 2020, CLIN COLORECTAL CANC, V19, P291, DOI 10.1016/j.clcc.2020.06.005; Heinemann V, 2015, EUR J CANCER, V51, P1927, DOI 10.1016/j.ejca.2015.06.116; Ikoma T, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08271-z; LaPointe LC, 2008, PHYSIOL GENOMICS, V33, P50, DOI 10.1152/physiolgenomics.00185.2006; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Pietrantonio F, 2015, ONCOLOGIST, V20, P1261, DOI 10.1634/theoncologist.2015-0171; Sastre J, 2015, EUR J CANCER, V51, P1371, DOI 10.1016/j.ejca.2015.04.013; Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473; Seymour MT, 2011, LANCET, V377, P1749, DOI 10.1016/S0140-6736(11)60399-1; Siegel RL., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395; Soldevilla B, 2019, EUR J CANCER, V123, P118, DOI 10.1016/j.ejca.2019.09.008; Sorbye H, 2009, CANCER, V115, P4679, DOI 10.1002/cncr.24527; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Terazawa T, 2021, ONCOLOGIST, V26, P17, DOI 10.1002/ONCO.13523; van Leersum NJ, 2013, INT J CANCER, V132, P2157, DOI 10.1002/ijc.27871; Yamada Y, 2018, ANN ONCOL, V29, P624, DOI 10.1093/annonc/mdx816; Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738	26	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1083-7159	1549-490X		ONCOLOGIST	Oncologist	2022 AUG 10	2022										10.1093/oncolo/oyac145	http://dx.doi.org/10.1093/oncolo/oyac145		AUG 2022	10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	3Q5FT	35947993	Green Published, gold			2025-09-11	WOS:000838257600001
J	Ohno, A; Fujimori, N; Kaku, T; Matsumoto, K; Murakami, M; Teramatsu, K; Ueda, K; Hijioka, M; Aso, A; Ogawa, Y				Ohno, Akihisa; Fujimori, Nao; Kaku, Toyoma; Matsumoto, Kazuhide; Murakami, Masatoshi; Teramatsu, Katsuhito; Ueda, Keijiro; Hijioka, Masayuki; Aso, Akira; Ogawa, Yoshihiro			Puncture angle on an endoscopic ultrasound image is independently associated with unsuccessful guidewire manipulation of endoscopic ultrasound-guided hepaticogastrostomy: a retrospective study in Japan	CLINICAL ENDOSCOPY			English	Article						Bile ducts; Biliary tract; Endoscopy; Needles	BILIARY DRAINAGE; CHOLEDOCHODUODENOSTOMY; ERCP	Background/Aims: Although endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is performed globally, the procedure remains challenging. Guidewire manipulation is the most difficult step, and there are few reports on the factors associated with unsuccessful guidewire manipulation. This study aimed to assess the significance of the puncture angle on EUS images and identify the most effective guidewire rescue method for patients with unsuccessful guidewire manipulation. Methods: We retrospectively enrolled 115 patients who underwent EUS-HGS between May 2016 and April 2022 at two centers. The puncture angle between the needle and the intrahepatic bile duct was measured through EUS movie records. Results: Guidewire manipulation was unsuccessful in 28 patients. Receiver operating characteristic (ROC) curves identified an optimal puncture angle cutoff value of 85 degrees (cutoff value, 85 degrees; area under the ROC curve, 0.826; sensitivity, 85.7%; specificity, 81.6%). Multivariate analysis demonstrated that a puncture angle <85 degrees was a significant risk factor for unsuccessful guidewire manipulation (odds ratio, 19.8; 95% confidence interval, 6.42-61.5; p<0.001). Among the 28 unsuccessful cases, 24 patients (85.7%) achieved successful guidewire manipulation using various rescue methods. Conclusions: The puncture angle observed on EUS is crucial for guidewire manipulation. A puncture angle of <85 degrees was associated with unsuccessful guidewire manipulation.	[Ohno, Akihisa; Fujimori, Nao; Matsumoto, Kazuhide; Murakami, Masatoshi; Teramatsu, Katsuhito; Ueda, Keijiro; Aso, Akira; Ogawa, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan; [Ohno, Akihisa; Kaku, Toyoma; Hijioka, Masayuki] Natl Hosp Org Kyushu Med Ctr, Dept Gastroenterol, Clin Res Inst, Fukuoka, Japan	Kyushu University	Fujimori, N (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan.	fujimori.nao.239@m.kyushu-u.ac.jp		Ohno, Akihisa/0000-0003-1372-166X; Fujimori, Nao/0000-0003-4286-8804; Ogawa, Yoshihiro/0000-0002-0834-2836; Matsumoto, Kazuhide/0000-0003-0842-6500	JSPS KAKENHI [JP18K09945]; Grant of The Clinical Research Promotion Foundation (2022)	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grant of The Clinical Research Promotion Foundation (2022)	This work was supported in part by JSPS KAKENHI (grant number: JP18K09945) and the Grant of The Clinical Research Promotion Foundation (2022).	Artifon ELA, 2015, GASTROINTEST ENDOSC, V81, P950, DOI 10.1016/j.gie.2014.09.047; Cotton PB, 2010, GASTROINTEST ENDOSC, V71, P446, DOI 10.1016/j.gie.2009.10.027; Fugazza A, 2022, HEPATOB PANCREAT DIS, V21, P234, DOI 10.1016/j.hbpd.2022.03.003; Hara K, 2020, J HEPATO-BIL-PAN SCI, V27, P563, DOI 10.1002/jhbp.774; Isayama H, 2015, DIGEST ENDOSC, V27, P259, DOI 10.1111/den.12379; Kawakami H, 2017, ENDOSCOPY, V49, pE264, DOI 10.1055/s-0043-116014; Khan MA, 2016, DIGEST DIS SCI, V61, P684, DOI 10.1007/s10620-015-3933-0; Lee TH, 2016, CLIN GASTROENTEROL H, V14, P1011, DOI 10.1016/j.cgh.2015.12.032; Matsubara S, 2022, J CLIN MED, V11, DOI 10.3390/jcm11061591; Moole H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005154; Ogura T, 2022, GASTROINTEST ENDOSC, V96, P262, DOI 10.1016/j.gie.2022.03.013; Ogura T, 2021, ENDOSCOPY, V53, P369, DOI 10.1055/a-1199-5418; Ogura T, 2015, ENDOSCOPY, V47, pE583, DOI 10.1055/s-0034-1393381; Oh D, 2017, THER ADV GASTROENTER, V10, P42, DOI 10.1177/1756283X16671671; Ohno A, 2022, DIGEST DIS SCI, V67, P5676, DOI 10.1007/s10620-022-07555-z; Ohno A, 2022, ENDOSC ULTRASOUND, V11, P330, DOI 10.4103/EUS-D-21-00067; Sharaiha RZ, 2017, GASTROINTEST ENDOSC, V85, P904, DOI 10.1016/j.gie.2016.12.023; Uemura RS, 2018, J CLIN GASTROENTEROL, V52, P123, DOI 10.1097/MCG.0000000000000948; Ueno S, 2021, DIGEST ENDOSC, V33, pE109, DOI 10.1111/den.13993; Vila JJ, 2012, GASTROINTEST ENDOSC, V76, P1133, DOI 10.1016/j.gie.2012.08.001; Wang KX, 2016, GASTROINTEST ENDOSC, V83, P1218, DOI 10.1016/j.gie.2015.10.033	21	2	2	1	3	KOREAN SOC GASTROINTESTINAL ENDOSCOPY	SEOUL	2003 LG PALACE, 165-8 DONGGYO-DONG, MAPO-GU, SEOUL, 121-754, SOUTH KOREA	2234-2400	2234-2443		CLIN ENDOSC	Clin. Endosc.	SEP	2024	57	5					656	665		10.5946/ce.2023.244	http://dx.doi.org/10.5946/ce.2023.244			10	Gastroenterology & Hepatology	Emerging Sources Citation Index (ESCI)	Gastroenterology & Hepatology	P1E7V	39354833	gold, Green Submitted			2025-09-11	WOS:001375436900014
J	Morita, H; Abe, M; Suematsu, Y; Uehara, Y; Koyoshi, R; Fujimi, K; Ideishi, A; Takata, K; Kato, Y; Hirata, T; Yahiro, E; Morito, N; Kitajima, K; Satoh, A; Yoshimura, C; Ishida, S; Okutsu, S; Takahashi, K; Shinohara, Y; Sakaguchi, T; Katsuki, S; Tada, K; Fujii, T; Funakoshi, S; Hu, YP; Satoh, T; Ohnishi, H; Okamura, K; Mizuno, H; Arakawa, K; Asayama, K; Ohtsubo, T; Ishigami, T; Shibata, S; Fujita, T; Munakata, M; Ohishi, M; Ichihara, A; Katsuya, T; Mukoyama, M; Rakugi, H; Node, K; Arima, H; Miura, S				Morita, Hidetaka; Abe, Makiko; Suematsu, Yasunori; Uehara, Yoshinari; Koyoshi, Rie; Fujimi, Kanta; Ideishi, Akihito; Takata, Kohei; Kato, Yuta; Hirata, Tetsuo; Yahiro, Eiji; Morito, Natsumi; Kitajima, Ken; Satoh, Atsushi; Yoshimura, Chikara; Ishida, Shintaro; Okutsu, Shota; Takahashi, Koji; Shinohara, Yukiko; Sakaguchi, Takashi; Katsuki, Shiori; Tada, Kazuhiro; Fujii, Takako; Funakoshi, Shunsuke; Hu, Yaopeng; Satoh, Tomonori; Ohnishi, Hirofumi; Okamura, Keisuke; Mizuno, Hiroyuki; Arakawa, Kimika; Asayama, Kei; Ohtsubo, Toshio; Ishigami, Tomoaki; Shibata, Shigeru; Fujita, Takayuki; Munakata, Masanori; Ohishi, Mitsuru; Ichihara, Atsuhiro; Katsuya, Tomohiro; Mukoyama, Masashi; Rakugi, Hiromi; Node, Koichi; Arima, Hisatomi; Miura, Shin-ichiro			Resistance exercise has an antihypertensive effect comparable to that of aerobic exercise in hypertensive patients: a meta-analysis of randomized controlled trials	HYPERTENSION RESEARCH			English	Article						Hypertension; Aerobic exercise; Resistance exercise; Meta-analysis	FLOW-MEDIATED DILATION; RESTING BLOOD-PRESSURE; IMPACT; METAANALYSIS; ADULTS; MUSCLE; MEN	Hypertension increases the risk of cerebrovascular disease and death. In addition to aerobic exercise, which is currently recommended for its antihypertensive effects, recent studies have suggested that dynamic and isometric resistance exercises also have antihypertensive effects. However, the magnitude of the antihypertensive effect of such resistance exercises is not well known. To clarify the differences in these effects, we conducted an umbrella review of a meta-analysis of randomized controlled trials (RCTs). A systematic search was performed on the Ovid MEDLINE and Cochrane Library, covering the period from inception to August 1, 2023. Eligible studies were RCTs comparing the effects of exercise and non-exercise on office, home, or ambulatory blood pressure (BP) in hypertensive patients aged 18 years or older. A random effects model meta-analysis was performed to estimate the effect size across multiple studies. A sub-analysis determined outcomes by the type of exercise (aerobic exercise, dynamic resistance exercise, isometric resistance exercise, and combined exercise). Eighty-four RCTs with 5065 hypertensive patients were included in the study. All exercise significantly reduced systolic BP (SBP) and diastolic BP (DBP) compared to non-exercise (SBP:-7.52mmHg, 95% confidence interval [CI] -8.77 to -6.27, p<0.001; DBP: -4.36mmHg, 95% CI-5.15 to -3.57, p<0.001). There were no significant differences in the magnitude of the reduction in BP between the types of exercise (p for interaction=0.815 for SBP, p=0.417 for DBP). These data from 84 RCTs showed that exercise intervention significantly reduced BP and that resistance exercise has a similar antihypertensive effect to aerobic exercise in hypertensive patients.	[Morita, Hidetaka] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Dynam, Osaka, Japan; [Abe, Makiko; Yoshimura, Chikara; Ishida, Shintaro; Shinohara, Yukiko; Fujii, Takako; Funakoshi, Shunsuke; Arima, Hisatomi] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka, Japan; [Suematsu, Yasunori; Uehara, Yoshinari; Ideishi, Akihito; Kato, Yuta; Hirata, Tetsuo] Fukuoka Univ Hosp, Dept Cardiol, Fukuoka, Japan; [Uehara, Yoshinari] Fukuoka Univ, Fac Sports & Hlth Sci, Fukuoka, Japan; [Koyoshi, Rie] Fukuoka Univ Hosp, Div Med Safety Management, Fukuoka, Japan; [Fujimi, Kanta] Fukuoka Univ Hosp, Dept Rehabil, Fukuoka, Japan; [Takata, Kohei; Morito, Natsumi] Fukuoka Univ, Dept Clin Lab Med, Fac Med, Fukuoka, Japan; [Yahiro, Eiji] Fukuoka Univ Hosp, Postgrad Clin Training Ctr, Fukuoka, Japan; [Kitajima, Ken] Fukuoka Univ, Med Educ Ctr, Fac Med, Fukuoka, Japan; [Satoh, Atsushi] Kobe Pharmaceut Univ, Lab Epidemiol & Prevent, Kobe, Hyogo, Japan; [Okutsu, Shota] Fukuoka Univ, Sch Med, Dept Gen Med, Fac Med, Fukuoka, Japan; [Takahashi, Koji; Sakaguchi, Takashi; Katsuki, Shiori; Tada, Kazuhiro] Fukuoka Univ, Div Nephrol & Rheumatol, Dept Internal Med, Fac Med, Fukuoka, Japan; [Fujii, Takako] Shiga Univ Med Sci, NCD Epidemiol Res Ctr, Otsu, Shiga, Japan; [Hu, Yaopeng; Fujita, Takayuki] Fukuoka Univ, Dept Physiol, Sch Med, Fukuoka, Japan; [Satoh, Tomonori] Tohoku Rosai Hosp, Res Ctr Promot Hlth & Employment Support, Sendai, Miyagi, Japan; [Ohnishi, Hirofumi] Sapporo Med Univ, Sch Med, Dept Publ Hlth, Sapporo, Hokkaido, Japan; [Okamura, Keisuke] Imamura Hosp, Dept Cardiol, Saga, Japan; [Okamura, Keisuke] Imamura Hosp, Cardiovasc Ctr, Saga, Japan; [Mizuno, Hiroyuki] Jichi Med Univ, Sch Med, Div Cardiovasc Med, Shimotsuke, Tochigi, Japan; [Arakawa, Kimika] Kyushu Med Ctr, Dept Clin Lab, Natl Hosp Org, Fukuoka, Japan; [Asayama, Kei] Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Itabashi City, Tokyo, Japan; [Ohtsubo, Toshio] Fukuoka Red Cross Hosp, Dept Hypertens Internal Med, Fukuoka, Japan; [Ishigami, Tomoaki] Yokohama City Univ Med, Dept Cardiol, Yokohama, Kanagawa, Japan; [Shibata, Shigeru] Teikyo Univ, Sch Med, Dept Internal Med, Div Nephrol, Tokyo, Japan; [Munakata, Masanori] Tohoku Rosai Hosp, Res Ctr Promot Hlth & Employment Support, Sendai, Miyagi, Japan; [Ohishi, Mitsuru] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc Med & Hypertens, Kagoshima, Japan; [Ichihara, Atsuhiro] Tokyo Womens Med Univ, Dept Med, Tokyo, Japan; [Katsuya, Tomohiro] Katsuya Clin, Shinjuku City, Tokyo, Japan; [Mukoyama, Masashi] Kumamoto Univ, Dept Nephrol, Grad Sch Med Sci, Kumamoto, Japan; [Rakugi, Hiromi] Osaka Rosai Hosp, Osaka, Japan; [Node, Koichi] Saga Univ, Dept Cardiovasc Med, Saga, Japan; [Miura, Shin-ichiro] Fukuoka Univ, Dept Cardiol, Fac Med, Fukuoka, Japan	National Cerebral & Cardiovascular Center - Japan; Fukuoka University; Fukuoka University; Fukuoka University; Fukuoka University; Fukuoka University; Fukuoka University; Fukuoka University; Fukuoka University; Kobe Pharmaceutical University; Fukuoka University; Fukuoka University; Shiga University of Medical Science; Fukuoka University; Sapporo Medical University; Jichi Medical University; Teikyo University; Yokohama City University; Teikyo University; Kagoshima University; Tokyo Women's Medical University; Kumamoto University; Osaka Rosai Hospital; Saga University; Fukuoka University	Arima, H (corresponding author), Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka, Japan.; Miura, S (corresponding author), Fukuoka Univ, Dept Cardiol, Fac Med, Fukuoka, Japan.	harima@fukuoka-u.ac.jp; miuras@cis.fukuoka-u.ac.jp	ARAKAWA, KIMIKA/NYT-3357-2025; Rakugi, Hiromi/ADM-3795-2022; Asayama, Kei/H-5598-2011	Morita, Hidetaka/0000-0003-0467-9236; 				Agarwal D, 2009, HYPERTENSION, V54, P1393, DOI 10.1161/HYPERTENSIONAHA.109.135459; Badrov MB, 2016, EUR J APPL PHYSIOL, V116, P1289, DOI 10.1007/s00421-016-3366-2; Carlson DJ, 2014, MAYO CLIN PROC, V89, P327, DOI 10.1016/j.mayocp.2013.10.030; Cornelissen VA, 2005, HYPERTENSION, V46, P667, DOI 10.1161/01.HYP.0000184225.05629.51; Cornelissen VA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.004473; Cornelissen VA, 2011, HYPERTENSION, V58, P950, DOI 10.1161/HYPERTENSIONAHA.111.177071; Edwards JJ, 2022, J HYPERTENS, V40, P2299, DOI 10.1097/HJH.0000000000003261; Fecchio RY, 2023, HYPERTENS RES, V46, P1031, DOI 10.1038/s41440-023-01202-4; Gliemann L, 2015, ACTA PHYSIOL, V214, P210, DOI 10.1111/apha.12501; Green DJ, 2017, PHYSIOL REV, V97, P495, DOI 10.1152/physrev.00014.2016; Hanssen H, 2022, EUR J PREV CARDIOL, V29, P205, DOI 10.1093/eurjpc/zwaa141; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Igarashi Y, 2018, CLIN EXP HYPERTENS, V40, P378, DOI 10.1080/10641963.2017.1384483; Kelley GA, 2009, PREV MED, V48, P9, DOI 10.1016/j.ypmed.2008.10.010; Kim JS, 2005, AM J PHYSIOL-ENDOC M, V288, pE1110, DOI 10.1152/ajpendo.00464.2004; MacDonald HV, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003231; Mancia G, 2007, EUR HEART J, V28, P1462, DOI 10.1093/eurheartj/ehm236; Masson GS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094927; McGowan CL, 2007, EUR J APPL PHYSIOL, V99, P227, DOI 10.1007/s00421-006-0337-z; Murase S, 2023, NAT BIOMED ENG, V7, P1350, DOI 10.1038/s41551-023-01061-x; Pedralli ML, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64365-x; Rossi AM, 2013, CAN J CARDIOL, V29, P622, DOI 10.1016/j.cjca.2013.02.010; Sarelius I, 2010, ACTA PHYSIOL, V199, P349, DOI 10.1111/j.1748-1716.2010.02129.x; Umemura S, 2019, HYPERTENS RES, V42, P1235, DOI 10.1038/s41440-019-0284-9; Unger T, 2020, J HYPERTENS, V38, P982, DOI [10.1097/HJH.0000000000002453, 10.1161/HYPERTENSIONAHA.120.15026]; VanHoof R, 1996, INT J SPORTS MED, V17, P415, DOI 10.1055/s-2007-972871; Williams MA, 2007, CIRCULATION, V116, P572, DOI 10.1161/CIRCULATIONAHA.107.185214; Wright JT, 2015, NEW ENGL J MED, V373, P2103, DOI 10.1056/NEJMoa1511939; Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5	29	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0916-9636	1348-4214		HYPERTENS RES	Hypertens. Res.	FEB	2025	48	2					733	743		10.1038/s41440-024-01998-9	http://dx.doi.org/10.1038/s41440-024-01998-9		NOV 2024	11	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	X8N0T	39609644				2025-09-11	WOS:001425534900001
J	Hirai, M; Mori, M; Sakai, T; Oka, T; Watanabe, Y; Murata, M; Moriyoshi, K; Kawabata, H				Hirai, Masataka; Mori, Minako; Sakai, Tomomi; Oka, Tomomi; Watanabe, Yasuhiro; Murata, Masaki; Moriyoshi, Koki; Kawabata, Hiroshi			Management of Concurrent Immune Thrombocytopenia and Ulcerative Colitis: A Case Report and Literature Review	INTERNAL MEDICINE			English	Review						idiopathic thrombocytopenic purpura; immune thrombocytopenia; ulcerative colitis; mesalazine	INFLAMMATORY-BOWEL-DISEASE; PURPURA; COLECTOMY; GUIDELINES; PATIENT; ONSET	We herein report a case of concurrent immune thrombocytopenia (ITP) and ulcerative colitis (UC) that achieved remission following mesalazine treatment. A 16-year-old girl presented with severe thrombocytopenia, abdominal pain, and bloody stool. She was initially diagnosed with ITP and then was treated with prednisolone, resulting in an immediate improvement of symptoms. Upon tapering the steroids, the symptoms recurred, thus leading to a subsequent diagnosis of UC via colonoscopy. Treatment with mesalazine promptly induced the remission of both ITP and UC, which was sustained. We reviewed 24 previously documented cases in which the simultaneous flares of UC and ITP were successfully managed.	[Mori, Minako] NHO Kyoto Med Ctr, Dept Hematol, Kyoto, Japan; NHO Kyoto Med Ctr, Dept Gastroenterol, Kyoto, Japan; NHO Kyoto Med Ctr, Dept Diagnost Pathol, Kyoto, Japan		Mori, M (corresponding author), NHO Kyoto Med Ctr, Dept Hematol, Kyoto, Japan.	minako@kuhp.kyoto-u.ac.jp						Abdelmahmuod EA, 2021, CLIN CASE REP, V9, P1416, DOI 10.1002/ccr3.3783; Bauer WM, 1999, DIGEST DIS SCI, V44, P2330, DOI 10.1023/A:1026681426319; Chandra S, 2014, J COMM HOSP INT MED, V4, DOI 10.3402/jchimp.v4.23386; Dutra RD, 2022, CASE REP GASTROENTER, V16, P140, DOI 10.1159/000522379; Funato M, 2011, PEDIATR INT, V53, P771, DOI 10.1111/j.1442-200X.2010.03308.x; Higuchi LM, 2001, J PEDIATR GASTR NUTR, V33, P582, DOI 10.1097/00005176-200111000-00013; Hisada T, 2006, INTERNAL MED, V45, P87, DOI 10.2169/internalmedicine.45.1465; Iwasa T, 2017, INTERNAL MED, V56, P1331, DOI 10.2169/internalmedicine.56.7909; JINBO T, 1992, CLIN RHEUMATOL, V11, P408, DOI 10.1007/BF02207205; Kodaira M, 1999, AM J GASTROENTEROL, V94, P1408, DOI 10.1016/S0002-9270(99)00154-9; Mahajna H, 2023, J CROHNS COLITIS, V17, P722, DOI 10.1093/ecco-jcc/jjac179; Mares WGN, 2011, INFLAMM BOWEL DIS, V17, P864, DOI 10.1002/ibd.21327; McCaulley ME, 1996, J CLIN GASTROENTEROL, V23, P242, DOI 10.1097/00004836-199610000-00022; Miner RJ, 2001, J CLIN GASTROENTEROL, V32, P276, DOI 10.1097/00004836-200103000-00028; Mizuta Y, 2003, J GASTROENTEROL, V38, P884, DOI 10.1007/s00535-002-1166-4; Negoro A, 2014, INT J COLORECTAL DIS, V29, P1179, DOI 10.1007/s00384-014-1903-1; Neunert C, 2019, BLOOD ADV, V3, P3829, DOI 10.1182/bloodadvances.2019000966; Queliza K, 2017, ANN CLIN LAB SCI, V47, P226; Raine T, 2022, J CROHNS COLITIS, V16, P2, DOI 10.1093/ecco-jcc/jjab178; Rogler G, 2021, GASTROENTEROLOGY, V161, P1118, DOI 10.1053/j.gastro.2021.07.042; Singh AK, 2022, INFLAMM BOWEL DIS, V28, pE90, DOI 10.1093/ibd/izab324; Subki AH, 2022, J INFLAMM RES, V15, P6373, DOI 10.2147/JIR.S365094; Suzuki K, 2024, INTERNAL MED, V63, P665, DOI 10.2169/internalmedicine.2969-23; Takeuchi H, 2022, J CLIN MED, V11, DOI 10.3390/jcm11164822; Varderili Eser, 2003, Turk J Gastroenterol, V14, P270; Zlatanic J, 1997, AM J GASTROENTEROL, V92, P2285	26	0	0	1	1	JAPAN SOC INTERNAL MEDICINE	TOKYO	34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN	0918-2918	1349-7235		INTERNAL MED	Intern. Med.		2025	64	10					1569	1573		10.2169/internalmedicine.4424-24	http://dx.doi.org/10.2169/internalmedicine.4424-24		OCT 2024	5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3NR9G	39462593	Green Submitted, gold			2025-09-11	WOS:001342431900001
J	Terazawa, T; Kato, T; Goto, M; Ohta, K; Satake, H; Noura, S; Kagawa, Y; Kawakami, H; Hasegawa, H; Yanagihara, K; Shingai, T; Nakata, K; Kotaka, M; Hiraki, M; Konishi, K; Nakae, S; Sakai, D; Kurokawa, Y; Shimokawa, T; Tsujinaka, T; Satoh, T				Terazawa, Tetsuji; Kato, Takeshi; Goto, Masahiro; Ohta, Katsuya; Satake, Hironaga; Noura, Shingo; Kagawa, Yoshinori; Kawakami, Hisato; Hasegawa, Hiroko; Yanagihara, Kazuhiro; Shingai, Tatsushi; Nakata, Ken; Kotaka, Masahito; Hiraki, Masayuki; Konishi, Ken; Nakae, Shiro; Sakai, Daisuke; Kurokawa, Yukinori; Shimokawa, Toshio; Tsujinaka, Toshimasa; Satoh, Taroh			The Phase II Study of Panitumumab in ChemotherapyNaive Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results	ONCOLOGIST			English	Article						colorectal cancer; frail patient; elderly patients; panitumumab	EARLY TUMOR SHRINKAGE; SINGLE-AGENT PANITUMUMAB; OPEN-LABEL; BEVACIZUMAB; DEPTH; TRIAL; LOCATION	Background: We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis. Methods: Patients aged >= 65 years and considered unsuitable for intensive chemotherapy or aged >= 76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs). Results: Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8- 24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P =.120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P =.043]. Conclusion: Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528).	[Terazawa, Tetsuji; Goto, Masahiro] Osaka Med & Pharmaceut Univ, Ctr Canc Chemotherapy, Takatsuki, Japan; [Kato, Takeshi] Natl Hosp Org Osaka Natl Hosp, Dept Surg Gastroenterol, Higashiosaka, Osaka, Japan; [Ohta, Katsuya] Higashiosaka City Med Ctr, Dept Surg Gastroenterol, Osaka, Japan; [Satake, Hironaga] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan; [Noura, Shingo] Osaka Rosai Hosp, Dept Surg Gastroenterol, Sakai, Osaka, Japan; [Noura, Shingo] Toyonaka City Hosp, Dept Surg Gastroenterol, Toyonaka, Osaka, Japan; [Kagawa, Yoshinori] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan; [Kawakami, Hisato] Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan; [Hasegawa, Hiroko] Natl Hosp Org Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan; [Yanagihara, Kazuhiro] Kansai Elect Power Hosp, Dept Med Oncol, Osaka, Japan; [Shingai, Tatsushi] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan; [Nakata, Ken] Sakai City Med Ctr, Dept Surg, Sakai, Osaka, Japan; [Kotaka, Masahito] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan; [Hiraki, Masayuki] Itami City Hosp, Dept Surg, Itami, Hyogo, Japan; [Konishi, Ken] Hyogo Prefectural Nishinomiya Hosp, Dept Surg, Nishinomiya, Hyogo, Japan; [Nakae, Shiro] Mimihara Gen Hosp, Dept Med Oncol, Sakai, Osaka, Japan; [Sakai, Daisuke; Satoh, Taroh] Osaka Univ, Dept Frontier Sci Canc & Chemotherapy, Grad Sch Med, Suita, Osaka, Japan; [Kurokawa, Yukinori] Osaka Univ, Dept Gastroenterol Surg, Grad Sch Med, Osaka, Japan; [Shimokawa, Toshio] Wakayama Med Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka, Japan; [Tsujinaka, Toshimasa] Izumi City Gen Hosp, Ctr Canc, Izumi, Japan	Osaka Medical & Pharmaceutical University; Osaka National Hospital; Kobe City Medical Center General Hospital; Osaka Rosai Hospital; Kansai Rosai Hospital; Osaka National Hospital; University of Osaka; University of Osaka	Kato, T (corresponding author), Natl Hosp Org Osaka Natl Hosp, Dept Surg Gastroenterol, Chuo Ku, 2-1-14 Hoenzaka, Osaka 5400006, Japan.	ken-kato@momo.so-net.ne.jp	; Kawakami, Hisato/L-6845-2019; Satoh, Taroh/AAF-5193-2021; Satake, Hironaga/G-6243-2013	Kawakami, Hisato/0000-0002-3280-4850; Hiraki, Masayuki/0000-0001-6445-7390; 	Osaka Gastrointestinal Cancer Chemotherapy Study Group - Takeda Pharmaceutical Company Limited	Osaka Gastrointestinal Cancer Chemotherapy Study Group - Takeda Pharmaceutical Company Limited	This study was supported by Osaka Gastrointestinal Cancer Chemotherapy Study Group and funded by Takeda Pharmaceutical Company Limited.	Aarts MJ, 2010, EUR J CANCER, V46, P2681, DOI 10.1016/j.ejca.2010.04.026; Bekaii-Saab T, 2014, J NATL COMPR CANC NE, V12, P299, DOI 10.6004/jnccn.2014.0027; Boeckx N, 2017, ANN ONCOL, V28, P1862, DOI 10.1093/annonc/mdx119; Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015; Cremolini C, 2015, ANN ONCOL, V26, P1188, DOI 10.1093/annonc/mdv112; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; Froelich MF, 2020, CLIN COLORECTAL CANC, V19, P291, DOI 10.1016/j.clcc.2020.06.005; Heinemann V, 2015, EUR J CANCER, V51, P1927, DOI 10.1016/j.ejca.2015.06.116; Ikoma T, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08271-z; LaPointe LC, 2008, PHYSIOL GENOMICS, V33, P50, DOI 10.1152/physiolgenomics.00185.2006; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Pietrantonio F, 2015, ONCOLOGIST, V20, P1261, DOI 10.1634/theoncologist.2015-0171; Sastre J, 2015, EUR J CANCER, V51, P1371, DOI 10.1016/j.ejca.2015.04.013; Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473; Seymour MT, 2011, LANCET, V377, P1749, DOI 10.1016/S0140-6736(11)60399-1; Siegel RL., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395; Soldevilla B, 2019, EUR J CANCER, V123, P118, DOI 10.1016/j.ejca.2019.09.008; Sorbye H, 2009, CANCER, V115, P4679, DOI 10.1002/cncr.24527; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Terazawa T, 2021, ONCOLOGIST, V26, P17, DOI 10.1002/ONCO.13523; van Leersum NJ, 2013, INT J CANCER, V132, P2157, DOI 10.1002/ijc.27871; Yamada Y, 2018, ANN ONCOL, V29, P624, DOI 10.1093/annonc/mdx816; Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738	26	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1083-7159	1549-490X		ONCOLOGIST	Oncologist	JUL	2023	28	7					E565	E574		10.1093/oncolo/oyac145	http://dx.doi.org/10.1093/oncolo/oyac145			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	S2LI6	35947993	gold, Green Published			2025-09-11	WOS:001069532100009
J	Shirakawa, C; Shiroshita, A; Kimura, Y; Anan, K; Cong, Y; Tomii, K; Igei, H; Suzuki, J; Ohgiya, M; Nitawaki, T; Sato, K; Suzuki, H; Nakashima, K; Takeshita, M; Okuno, T; Yamada, A; Kataoka, Y				Shirakawa, Chigusa; Shiroshita, Akihiro; Kimura, Yuya; Anan, Keisuke; Cong, Yue; Tomii, Keisuke; Igei, Hiroshi; Suzuki, Jun; Ohgiya, Masahiro; Nitawaki, Tatsuya; Sato, Kenya; Suzuki, Hokuto; Nakashima, Kiyoshi; Takeshita, Masafumi; Okuno, Takehiro; Yamada, Atsushi; Kataoka, Yuki			Prognostic Factors for Discharge Directly Home in Patients With Thoracoscopic Surgery for Empyema: A Multicenter Retrospective Cohort Study	SURGICAL INFECTIONS			English	Article						empyema; prognosis; thoracic surgery; video-assisted	SURGICAL-TREATMENT; THORACIC-SURGERY; MANAGEMENT; RISK; DECORTICATION; OCTOGENARIANS; PREDICTION; GUIDELINES; IDENTIFY	Background: Video-assisted thoracoscopic surgery is a widely recommended treatment for empyema in advanced stages. However, only a few studies have evaluated prognostic factors among patients with empyema who underwent video-assisted thoracoscopic surgery. Furthermore, no studies have evaluated predictors of direct discharge home. Patients and Methods: This multicenter retrospective cohort study included 161 patients with empyema who underwent video-assisted thoracoscopic surgery in five acute-care hospitals. The primary outcome was the probability of direct discharge home. The secondary outcome was the length of hospital stay after surgery. We broadly assessed pre-operative factors and performed univariable logistic regression for the direct discharge home and univariable gamma regression for the length of hospital stay after surgery. Results: Of the 161 included patients, 74.5% were directly discharged home. Age (>70 years; -24.3%); altered mental status (-33.4%); blood urea nitrogen (>22.4mg/dL; -19.4%); and pleural pH (<7.2; -17.6%) were associated with high probabilities of not being directly discharged home. Fever (15.2%) and albumin (> 2.7g/dL; 20.2%) were associated with high probabilities of being directly discharged home. The median length of stay after surgery was 19 days. Age (>70 years; 6.2 days); altered mental status (5.6 days); purulence (2.7 days); pleural thickness (>2cm; 5.1 days); bronchial fistula (14.6 days); albumin (>2.7g/dL; 3.1 days); and C-reactive protein (>20mg/dL; 3.6 days) were associated with a longer post-operation hospital stay. Conclusions: Physicians should consider using these prognostic factors to predict non-direct discharge to the home for patients with empyema.	[Shirakawa, Chigusa; Tomii, Keisuke] Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojimaminamimachi,Chuo Ku, Kobe, Hyogo 6500047, Japan; [Shiroshita, Akihiro; Suzuki, Hokuto; Nakashima, Kiyoshi; Takeshita, Masafumi; Okuno, Takehiro; Yamada, Atsushi] Ichinomiyanishi Hosp, Dept Resp Med, Ichinomiya, Aichi, Japan; [Shiroshita, Akihiro] Vanderbilt Univ, Div Epidemiol, Dept Med, Sch Med, Nashville, TN USA; [Kimura, Yuya; Igei, Hiroshi; Suzuki, Jun; Ohgiya, Masahiro] Natl Hosp Org Tokyo Hosp, Dept Resp Med, Ctr Pulm Dis, Kiyose, Tokyo, Japan; [Anan, Keisuke; Nitawaki, Tatsuya] Saiseikai Kumamoto Hosp, Div Resp Med, Kumamoto City, Kumamoto, Kumamoto, Japan; [Anan, Keisuke; Kataoka, Yuki] Sci Res Works Peer Support Grp SRWS PSG, Osaka, Osaka, Japan; [Cong, Yue] Fukushima Med Univ, Dept Minimally Invas Surg & Med Oncol, Fukushima, Fukushima, Japan; [Cong, Yue] Univ Tokyo Hosp, Dept Thorac Surg, Bunkyo Ku, Tokyo, Japan; [Sato, Kenya] Saiseikai Yokohamashi Tobu Hosp, Dept Thorac Med, Yokohama, Kanagawa, Japan; [Kataoka, Yuki] Kyoto Min Iren Asukai Hosp, Dept Internal Med, Kyoto, Kyoto, Japan; [Kataoka, Yuki] Kyoto Univ, Clin Epidemiol Sect, Dept Community Med, Grad Sch Med, Kyoto, Kyoto, Japan; [Kataoka, Yuki] Kyoto Univ, Dept Healthcare Epidemiol, Grad Sch Med, Sch Publ Hlth, Kyoto, Kyoto, Japan	Kobe City Medical Center General Hospital; Vanderbilt University; Saiseikai Kumamoto Hospital; Fukushima Medical University; University of Tokyo; Kyoto University; Kyoto University	Shirakawa, C (corresponding author), Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojimaminamimachi,Chuo Ku, Kobe, Hyogo 6500047, Japan.	grace.shirakawa@gmail.com	SUZUKI, JUN/ADJ-4146-2022; Kimura, Yuya/KYP-1829-2024; KATAOKA, Yuki/I-6026-2019	Kimura, Yuya/0000-0003-1649-0596; 	Ichinomiyanishi Hospital; Southern Tohoku Hospital; Kobe City Medical Center General Hospital	Ichinomiyanishi Hospital; Southern Tohoku Hospital; Kobe City Medical Center General Hospital	This work was supported by Ichinomiyanishi Hospital and Southern Tohoku Hospital. The English editing and literature ordering fees were supported by Kobe City Medical Center General Hospital (profit organization, funding number: none). Costs for data export and preservation were supported by Southern Tohoku Hospital (profit organization, funding number: none). The funders played no role in the study design, study execution, data analyses, data interpretation, or decision to submit the results.	Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; Bardakci H, 2007, ANN THORAC SURG, V83, P483, DOI 10.1016/j.athoracsur.2006.09.047; Benjamin SR, 2021, INDIAN J THORAC CARD, V37, P274, DOI 10.1007/s12055-020-01085-x; Casali Christian, 2009, Interact Cardiovasc Thorac Surg, V9, P74, DOI 10.1510/icvts.2009.203190; Colicc GL, 2000, CHEST, V118, P1158, DOI 10.1378/chest.118.4.1158; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Godfrey MS, 2019, SEMIN RESP CRIT CARE, V40, P361, DOI 10.1055/s-0039-1694699; Handy JR, 2012, THORAC SURG CLIN, V22, P487, DOI 10.1016/j.thorsurg.2012.07.010; HIMELMAN RB, 1986, CHEST, V90, P852, DOI 10.1378/chest.90.6.852; Huang HC, 1999, CHEST, V115, P751, DOI 10.1378/chest.115.3.751; Khemasuwan D, 2018, CHEST, V154, P550, DOI 10.1016/j.chest.2018.01.037; Lala A, 2021, J THORAC CARDIOV SUR, V162, P1769, DOI 10.1016/j.jtcvs.2020.02.084; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Marks DJB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030074; MURASHIMA S., 2000, Nursing and Health Sciences, V2, p, P153, DOI DOI 10.1046/J.1442-2018.2000.00051.X; Okiror L, 2014, EUR J CARDIO-THORAC, V46, P901, DOI 10.1093/ejcts/ezu104; Olgac G, 2005, THORAC CARDIOV SURG, V53, P318, DOI 10.1055/s-2005-865604; Pattakos G, 2012, J AM COLL SURGEONS, V214, P140, DOI 10.1016/j.jamcollsurg.2011.11.003; Rady MY, 2004, AM HEART J, V147, P347, DOI 10.1016/j.ahj.2003.05.001; Rahman NM, 2014, CHEST, V145, P848, DOI 10.1378/chest.13-1558; Rahman NM, 2011, NEW ENGL J MED, V365, P518, DOI 10.1056/NEJMoa1012740; Rubin DonaldB., 1987, MULTIPLE IMPUTATIONS, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schweigert M, 2016, SURG-J R COLL SURG E, V14, P69, DOI 10.1016/j.surge.2014.05.002; Shen KR, 2017, J THORAC CARDIOV SUR, V153, pE129, DOI 10.1016/j.jtcvs.2017.01.030; Shiroshita A, 2023, ANN AM THORAC SOC, V20, P807, DOI 10.1513/AnnalsATS.202210-868OC; Spaziano M, 2010, J HEART VALVE DIS, V19, P524; Stefani A, 2013, ANN THORAC SURG, V96, P1812, DOI 10.1016/j.athoracsur.2013.06.013; Subotic D, 2018, BREATHE, V14, P302, DOI 10.1183/20734735.025718; Tsai YM, 2019, SURG INFECT, V20, P607, DOI 10.1089/sur.2018.239; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013	30	0	0	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-2964	1557-8674		SURG INFECT	Surg. Infect.	MAR 1	2024	25	2					147	154		10.1089/sur.2023.193	http://dx.doi.org/10.1089/sur.2023.193		FEB 2024	8	Infectious Diseases; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Infectious Diseases; Surgery	A3G5Z	38381952				2025-09-11	WOS:001173727800001
J	Persano, M; Casadei-Gardini, A; Tada, T; Suda, G; Shimose, S; Kudo, M; Rossari, F; Yoo, C; Cheon, J; Finkelmeier, F; Lim, HY; Presa, J; Masi, G; Bergamo, F; Amadeo, E; Vitiello, F; Kumada, T; Sakamoto, N; Iwamoto, H; Aoki, T; Chon, HJ; Himmelsbach, V; Iavarone, MA; Cabibbo, G; Montes, M; Foschi, FG; Vivaldi, C; Solda, C; Sho, T; Niizeki, T; Nishida, N; Steup, C; Bruccoleri, M; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Hiraoka, A; Tada, F; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Imai, M; Kosaka, H; Naganuma, A; Koizumi, Y; Nakamura, S; Kaibori, M; Iijima, H; Hiasa, Y; Mascia, L; Foti, S; Camera, S; Piscaglia, F; Scartozzi, M; Cascinu, S; Rimini, M				Persano, Mara; Casadei-Gardini, Andrea; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Rossari, Federico; Yoo, Changhoon; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Bergamo, Francesca; Amadeo, Elisabeth; Vitiello, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; Iavarone, Massimo Alberto; Cabibbo, Giuseppe; Montes, Margarida; Foschi, Francesco Giuseppe; Vivaldi, Caterina; Solda, Caterina; Sho, Takuya; Niizeki, Takashi; Nishida, Naoshi; Steup, Christoph; Bruccoleri, Mariangela; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimura, Takashi; Hatanaka, Takeshi; Kakizaki, Satoru; Shimada, Noritomo; Kawata, Kazuhito; Hiraoka, Atsushi; Tada, Fujimasa; Ohama, Hideko; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Imai, Michitaka; Kosaka, Hisashi; Naganuma, Atsushi; Koizumi, Yohei; Nakamura, Shinichiro; Kaibori, Masaki; Iijima, Hiroko; Hiasa, Yoichi; Mascia, Luigi; Foti, Silvia; Camera, Silvia; Piscaglia, Fabio; Scartozzi, Mario; Cascinu, Stefano; Rimini, Margherita			Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study	ONCOLOGY			English	Article						Atezolizumab plus bevacizumab; Lenvatinib; Sorafenib	REGORAFENIB	Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC. This real-world study aimed to compare outcomes reached by lenvatinib and sorafenib second-line therapy in this setting. Methods: The overall cohort included 891 patients with HCC from 5 countries treated with atezolizumab plus bevacizumab in first-line setting between October 2018 and April 2022. At the data cut-off (May 2022), 41.5% of patients were continuing a first-line treatment, 5.5% were lost at follow-up, and 53.0% of patients had progressive disease after first-line therapy. 51.5% of patients with progressive disease received a second-line treatment, while 48.5% did not receive any subsequent therapy. Between patients receiving second-line treatment, 11.1% of patients underwent transarterial chemoembolization, 21.0% received sorafenib, 35.4% underwent lenvatinib, and 32.5% were treated with other drugs. Results: Lenvatinib second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; hazard ratio [HR]: 2.24) compared to sorafenib subgroup that reached a mOS of 14.3 months. The multivariate analysis highlighted albumin-bilirubin 1 grade (p < 0.01; HR: 5.23) and lenvatinib second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factors for OS. The forest plot highlighted a positive trend in terms of OS in favor of patients treated with lenvatinib second-line regardless of baseline characteristics before first-line therapy. Conclusion: These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib.	[Persano, Mara] ARNAS Brotzu, A Businco Canc Ctr, Med Oncol, Cagliari, Italy; [Persano, Mara] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy; [Casadei-Gardini, Andrea; Rossari, Federico; Amadeo, Elisabeth; Vitiello, Francesco; Camera, Silvia; Piscaglia, Fabio; Cascinu, Stefano; Rimini, Margherita] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Hosp, Dept Oncol, Milan, Italy; [Tada, Toshifumi] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Japan; [Suda, Goki; Sakamoto, Naoya; Sho, Takuya] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Japan; [Shimose, Shigeo] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan; [Kudo, Masatoshi] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan; [Rossari, Federico] IRCCS San Raffaele Sci Inst Hosp, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy; [Yoo, Changhoon] Univ Ulsan, Coll Med, ASAN Med Ctr, Dept Oncol, Seoul, South Korea; [Cheon, Jaekyung] CHA Univ, CHA Bundang Med Ctr, Dept Med Oncol, Sch Med, Seongnam, South Korea; [Finkelmeier, Fabian] Goethe Univ, Univ Hosp Frankfurt, Dept Internal Med 1, Div Gastroenterol, Frankfurt, Germany; [Lim, Ho Yeong] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea; [Presa, Jose; Montes, Margarida] Liver Unit CHTMAD, Vila Real, Portugal; [Masi, Gianluca] Univ Hosp Pisa, Unit Med Oncol 2, Pisa, Italy; [Masi, Gianluca] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy; [Bergamo, Francesca] IRCCS, Veneto Inst Oncol IOV, Oncol Unit 1, Padua, Italy; [Kumada, Takashi] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan; [Iavarone, Massimo Alberto] Fdn IRCCS CaGranda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy; [Cabibbo, Giuseppe] Univ Palermo, Dept Hlth Promot Mother & Child Care, Sect Gastroenterol & Hepatol, Internal Med & Med Specialties PROMISE, Palermo, Italy; [Foschi, Francesco Giuseppe] Osped Faenza, Dept Internal Med, Faenza, Italy; [Hirooka, Masashi; Koizumi, Yohei; Hiasa, Yoichi] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Matsuyama, Ehime, Japan; [Kariyama, Kazuya] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan; [Tani, Joji] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan; [Atsukawa, Masanori; Okubo, Tomomi] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan; [Takaguchi, Koichi] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Japan; [Itobayashi, Ei] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan; [Tsuji, Kunihiko] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan; [Ishikawa, Toru; Imai, Michitaka] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan; [Tajiri, Kazuto] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan; [Ochi, Hironori] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Japan; [Yasuda, Satoshi] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan; [Toyoda, Hidenori; Ogawa, Chikara] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Japan; [Niizeki, Takashi] Hyogo Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Nishinomiya, Japan; [Hatanaka, Takeshi] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Japan; [Kakizaki, Satoru] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Japan; [Shimada, Noritomo] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Japan; [Kawata, Kazuhito] Hamamatsu Univ Sch Med, Dept Hepatol, Hamamatsu, Japan; [Hiraoka, Atsushi; Tada, Fujimasa; Ohama, Hideko] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan; [Kosaka, Hisashi] Kansai Med Univ, Dept Surg, Osaka, Japan; [Naganuma, Atsushi] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Japan; [Piscaglia, Fabio] IRCCS Azienda Osped Univ Bologna, Div Internal Med Hepatobiliary & Immunoallerg Dis, Bologna, Italy; [Scartozzi, Mario] Univ Cagliari, Med Oncol, Cagliari, Italy; [Scartozzi, Mario] Univ Hosp Cagliari, Cagliari, Italy	University of Cagliari; Vita-Salute San Raffaele University; Hokkaido University; Kurume University; Kindai University (Kinki University); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Ulsan; Asan Medical Center; Pochon Cha University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Pisa; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Palermo; Ehime University; Kagawa University; Nippon Medical School; Teine Keijinkai Hospital; University of Toyama; Matsuyama Red Cross Hospital; Ogaki Municipal Hospital; Hyogo Medical University; Hamamatsu University School of Medicine; Kansai Medical University; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Cagliari	Persano, M (corresponding author), ARNAS Brotzu, A Businco Canc Ctr, Med Oncol, Cagliari, Italy.; Persano, M (corresponding author), Univ Cagliari, Dept Biomed Sci, Cagliari, Italy.	marapersano@alice.it	Ohama, Hideko/HJH-2482-2023; Kudo, Masatoshi/AAA-9744-2019; Hirooka, Masashi/JUF-2562-2023; Soldà, Caterina/AAI-3301-2021; Cabibbo, Giuseppe/K-2966-2018; Hatanaka, Takeshi/AAT-1609-2021; Finkelmeier, Fabian/J-8185-2019; Lim, Ho Yeong/KBA-8868-2024; Nishida, Naoshi/AFV-2598-2022; Foschi, Francesco/LRB-6334-2024; Hiraoka, Atsushi/AFR-0440-2022; Gardini, Andrea/AAA-6985-2022; Casadei gardini, Andrea/F-1830-2016; Vivaldi, Caterina/AAD-8742-2019; Bergamo, Francesca/AAB-9010-2019; Hiasa, Yoichi/ABD-2759-2021	Foschi, Francesco Giuseppe/0000-0002-8216-0918; Presa Ramos, Jose/0000-0003-0861-4296; Casadei gardini, Andrea/0000-0001-6289-7202; Amadeo, Elisabeth/0009-0007-6249-5159; 				Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Abou-Alfa GK, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100070, 10.1056/EVIDoa2100070]; Ben Khaled N, 2022, FUTURE ONCOL, V18, P1423, DOI 10.2217/fon-2021-1261; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Cabibbo G, 2021, LIVER CANCER, DOI 10.1159/000520278; Chan SL, 2024, J HEPATOL, V81, DOI 10.1016/j.jhep.2024.03.033; Chen YH, 2023, ANTICANCER RES, V43, P1377, DOI 10.21873/anticanres.16286; Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Falette-Puisieux M, 2023, THER ADV MED ONCOL, V15, DOI 10.1177/17588359231189425; Finn RS, 2023, J CLIN ONCOL, V41, P518; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; Hiraoka A, 2023, ONCOLOGY-BASEL, V101, P624, DOI 10.1159/000531316; Kudo M, 2019, CANCERS, V11, DOI 10.3390/cancers11081084; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Lee CK, 2023, ANN ONCOL, V34, pS603, DOI 10.1016/j.annonc.2023.09.2115; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; [Anonymous], 2021, Nat Rev Dis Primers, V7, P7, DOI [10.1038/s41572-021-00245-6, 10.1038/s41572-020-00240-3, 10.1038/s41572-021-00245-6]; Ntellas P., 2024, Am Soc Clin Oncol Educ Book, V44; Osa A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.59125; Peng ZW, 2023, J CLIN ONCOL, V41, P117, DOI 10.1200/JCO.22.00392; Persano M, 2023, EUR J CANCER, V189, DOI 10.1016/j.ejca.2023.05.021; Persano M, 2023, EXPERT REV ANTICANC, V23, P19, DOI 10.1080/14737140.2023.2156340; Persano M, 2023, J CANCER RES CLIN, V149, P5591, DOI 10.1007/s00432-022-04512-1; Reig M, 2022, J HEPATOL, V76, P681, DOI 10.1016/j.jhep.2021.11.018; Rimini M, 2023, TARGET ONCOL, V18, P221, DOI 10.1007/s11523-023-00953-x; Rimini M, 2023, J CANCER RES CLIN, V149, P7565, DOI 10.1007/s00432-023-04678-2; Sangro B, 2024, ANN ONCOL, V35, P448, DOI 10.1016/j.annonc.2024.02.005; Shimose S, 2021, CANCERS, V13, DOI 10.3390/cancers13010160; Tohyama O, 2014, J THROID RES, V2014, DOI 10.1155/2014/638747; Tomonari T, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022782; Wang K, 2022, FUTURE ONCOL, V18, P3367, DOI 10.2217/fon-2022-0188; Yamauchi M, 2020, CLIN TRANSL GASTROEN, V11; Yano S, 2023, CANCERS, V15, DOI 10.3390/cancers15225406; Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564; Yoo C, 2021, LIVER CANCER, V10, P107, DOI 10.1159/000512781; Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6	39	1	1	2	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0030-2414	1423-0232		ONCOLOGY-BASEL	Oncology	MAY	2025	103	6					456	468		10.1159/000541018	http://dx.doi.org/10.1159/000541018		OCT 2024	13	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	3SW6P	39396495				2025-09-11	WOS:001424703700001
J	Mitsunaga, S; Ikeda, M; Nomura, S; Morizane, C; Todaka, A; Yamamoto, N; Kamata, K; Yanagibashi, H; Mizuno, N; Kawamoto, Y; Gotoh, K; Shirakawa, H; Okano, N; Nomura, T; Tanaka, K; Takahashi, A; Yagi, S; Ohta, K; Takayama, Y; Miwa, H; Nagano, H; Kojima, Y; Hisano, T; Tahara, M; Sakuma, Y; Arai, H; Nakamura, I; Katayama, H; Konishi, M; Ueno, M				Mitsunaga, Shuichi; Ikeda, Masafumi; Nomura, Shogo; Morizane, Chigusa; Todaka, Akiko; Yamamoto, Naoto; Kamata, Ken; Yanagibashi, Hiroo; Mizuno, Nobumasa; Kawamoto, Yasuyuki; Gotoh, Kunihito; Shirakawa, Hirofumi; Okano, Naohiro; Nomura, Tatsuya; Tanaka, Kazunari; Takahashi, Amane; Yagi, Shintaro; Ohta, Koji; Takayama, Yukiko; Miwa, Haruo; Nagano, Hiroaki; Kojima, Yasushi; Hisano, Terumasa; Tahara, Munenori; Sakuma, Yasunaru; Arai, Hiroyuki; Nakamura, Ikuo; Katayama, Hiroshi; Konishi, Masaru; Ueno, Makoto		Hepatobiliary Pancreatic Oncology Grp; Japan Clinical Oncology Grp JCOG HBPOG	5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article; Early Access						5-FU metabolic pathway; adjuvant; biliary tract cancer; DPD; S-1	DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; EXPRESSION LEVELS; MESSENGER-RNA; THYMIDINE PHOSPHORYLASE; SENSITIVITY; TUMORS; CELLS	background: S- 1, an oral fluoropyrimidine derivative, is standard adjuvant therapy for resected biliary tract cancer (BTC), based on the results of the JCOG1202, a phase III trial evaluating the survival benefit with adjuvant S- 1 following curative resection for BTC compared to surgery alone. This multicenter ancillary study of the JCOG1202 aimed to evaluate the prognostic impact of the 5- fluorouracil (5- FU) metabolic pathway genes including thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).<br /> Methods: The 5- FU metabolic pathway genes were measured in tumor cells from formalin- fixed paraffin- embedded resected specimens from 183 patients (surgery alone: n= 94; adjuvant S- 1: n= 89). We randomly divided them into training (n= 96) and validation sets (n= 87) for evaluating the interaction between gene levels and RFS benefits in the treatment arm.<br /> Results: RFS benefits of adjuvant S- 1 were observed in the low DPD (HR = 0.440 and 0.748, respectively in the training and validation sets) and the low TP groups (HR = 0.709 and 0.602, respectively). Clinicopathological characteristics were well balanced between low and high DPD populations. More advanced stage tumors were observed in high TP populations as compared to those in low TP populations (p= .0332).<br /> Conclusion: The results suggest the RFS benefit of adjuvant S- 1 in resected BTC patients with low DPD and low TP gene expressions.	[Mitsunaga, Shuichi; Ikeda, Masafumi] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwan, Kashiwa, Chiba 277 8577, Japan; [Mitsunaga, Shuichi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Biomarker Discovery, Kashiwa, Japan; [Nomura, Shogo; Katayama, Hiroshi] Natl Canc Ctr, JCOG Data Ctr, Operat Off, Tokyo, Japan; [Morizane, Chigusa] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan; [Todaka, Akiko] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Sunto, Shizuoka, Japan; [Yamamoto, Naoto] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan; [Kamata, Ken] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan; [Yanagibashi, Hiroo] Chiba Canc Ctr, Dept Hepatobiliary & Pancreat Surg, Chiba, Japan; [Mizuno, Nobumasa] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan; [Kawamoto, Yasuyuki] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan; [Gotoh, Kunihito] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Shirakawa, Hirofumi] Tochigi Canc Ctr, Dept Hepatobiliary Pancreat Surg, Utsunomiya, Tochigi, Japan; [Okano, Naohiro] Kyorin Univ, Fac Med, Dept Med Oncol, Tokyo, Japan; [Nomura, Tatsuya] Niigata Canc Ctr Hosp, Dept Digest Surg, Niigata, Japan; [Tanaka, Kazunari] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan; [Takahashi, Amane] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan; [Yagi, Shintaro] Kanazawa Univ, Dept Hepatobiliary Pancreat Surg & Transplantat, Kanazawa, Japan; [Ohta, Koji] NHO Shikoku Canc Ctr, Dept Digest Surg, Matsuyama, Ehime, Japan; [Takayama, Yukiko] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, Tokyo, Japan; [Miwa, Haruo] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Japan; [Nagano, Hiroaki] Yamaguchi Univ, Dept Gastroenterol Breast & Endocrine Surg, Grad Sch Med, Ube, Japan; [Kojima, Yasushi] Natl Ctr Global Hlth & Med, Dept Gastroenterol, Tokyo, Japan; [Hisano, Terumasa] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan; [Tahara, Munenori] Sapporo Kosei Gen Hosp, Dept Surg Pathol, Sapporo, Japan; [Sakuma, Yasunaru] Jichi Med Univ, Dept Surg, Shimotsuke, Japan; [Arai, Hiroyuki] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Japan; [Nakamura, Ikuo] Hyogo Med Univ, Dept Gastroenterol Surg, Nishinomiya, Hyogo, Japan; [Konishi, Masaru] Natl Canc Ctr Hosp East, Dept Hepatobiliary Pancreat Surg, Kashiwa, Chiba, Japan; [Ueno, Makoto] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Med Oncol, Yokohama, Kanagawa, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Shizuoka Cancer Center; Kanagawa Prefectural Cancer Center; Kindai University (Kinki University); Chiba Cancer Center; Aichi Cancer Center; Hokkaido University; Osaka National Hospital; Tochigi Prefectural Cancer Center; Kyorin University; Teine Keijinkai Hospital; Kanazawa University; Tokyo Women's Medical University; Yokohama City University; Yamaguchi University; Japan Institute for Health Security (JIHS); National Center for Global Health & Medicine - Japan; Kyushu Cancer Center; Sapporo Kosei General Hospital; Jichi Medical University; Saint Marianna University; Hyogo Medical University; National Cancer Center - Japan; Kanagawa Prefectural Cancer Center	Mitsunaga, S (corresponding author), Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwan, Kashiwa, Chiba 277 8577, Japan.	smitsuna@east.ncc.go.jp	; Morizane, Chigusa/AFV-4780-2022; Takayama, Yukiko/AAA-3070-2020; Kawamoto, Yasuyuki/GWQ-7700-2022	Kawamoto, Yasuyuki/0000-0002-7706-0015; 	Japan Agency for Medical Research and Development [JP16ck0106079, JP17ck0106350]; Health and Labor Sciences Research Expenses for Commission; Applied Research for Innovative Treatment of Cancer from the Ministry of Health, Labor, and Welfare [H26- 076]; National Cancer Center Research and Development Fund [2020-J-3, 2023-J-03, 23-A-22, 26-A-4, 29-A-3]	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Health and Labor Sciences Research Expenses for Commission; Applied Research for Innovative Treatment of Cancer from the Ministry of Health, Labor, and Welfare; National Cancer Center Research and Development Fund(National Cancer Center - Japan)	Japan Agency for Medical Research and Development, Grant/Award Number: JP16ck0106079 and JP17ck0106350;the Health and Labor Sciences Research Expenses for Commission, and the Applied Research for Innovative Treatment of Cancer from the Ministry of Health, Labor, and Welfare, Grant/Award Number: H26- 076; the National Cancer Center Research and Development Fund, Grant/Award Number: 2020-J-3, 2023-J-03, 23-A-22, 26-A-4 and 29-A-3	Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Freidlin B, 2014, NAT REV CLIN ONCOL, V11, P81, DOI 10.1038/nrclinonc.2013.218; Fukui Y, 2008, INT J MOL MED, V22, P709, DOI 10.3892/ijmm_00000076; Habara K, 2001, JPN J CANCER RES, V92, P1127, DOI 10.1111/j.1349-7006.2001.tb01068.x; Hahnvajanawong C, 2012, WORLD J GASTROENTERO, V18, P3955, DOI 10.3748/wjg.v18.i30.3955; Ishikawa Y, 1999, CLIN CANCER RES, V5, P883; Iwahashi S, 2012, SURG TODAY, V42, P565, DOI 10.1007/s00595-012-0118-8; Kim KW, 2013, MOL CLIN ONCOL, V1, P987, DOI 10.3892/mco.2013.166; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li SL, 2020, CELL BIOCHEM FUNCT, V38, P743, DOI 10.1002/cbf.3541; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morine Y, 2012, SURG TODAY, V42, P135, DOI 10.1007/s00595-011-0054-z; Nakachi K, 2023, LANCET, V401, P195, DOI 10.1016/S0140-6736(22)02038-4; Nakata B, 2004, DIGEST DIS SCI, V49, P60, DOI 10.1023/B:DDAS.0000011603.40133.f9; Naruke A, 2015, GASTRIC CANCER, V18, P262, DOI 10.1007/s10120-014-0357-z; PETERS GJ, 1986, CANCER RES, V46, P20; Sato K, 2006, INT J ONCOL, V29, P429; Shirasaka T, 1996, CANCER RES, V56, P2602; Sun XJ, 2020, PATHOL ONCOL RES, V26, P121, DOI 10.1007/s12253-018-00563-3; Thanasai J, 2010, WORLD J GASTROENTERO, V16, P1631, DOI 10.3748/wjg.v16.i13.1631; Zhang C, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/9202676	21	0	0	5	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	2024 SEP 25	2024										10.1002/jhbp.12071	http://dx.doi.org/10.1002/jhbp.12071		SEP 2024	11	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	G9A8I	39318258				2025-09-11	WOS:001319489600001
J	Ohno, A; Fujimori, N; Kaku, T; Matsumoto, K; Murakami, M; Teramatsu, K; Ueda, K; Hijioka, M; Aso, A; Ogawa, Y				Ohno, Akihisa; Fujimori, Nao; Kaku, Toyoma; Matsumoto, Kazuhide; Murakami, Masatoshi; Teramatsu, Katsuhito; Ueda, Keijiro; Hijioka, Masayuki; Aso, Akira; Ogawa, Yoshihiro			Puncture angle on an endoscopic ultrasound image is independently associated with unsuccessful guidewire manipulation of endoscopic ultrasound-guided hepaticogastrostomy: a retrospective study in Japanese two centers	CLINICAL ENDOSCOPY			English	Article; Early Access						Bile ducts; Biliary tract; Endoscopy; Needles	BILIARY DRAINAGE; CHOLEDOCHODUODENOSTOMY; ERCP	Background/Aims: Although endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is performed globally, the procedure remains challenging. Guidewire manipulation is the most difficult step, and there are few reports on the factors associated with unsuccessful guidewire manipulation. This study aimed to assess the significance of the puncture angle on EUS images and identify the most effective guidewire rescue method for patients with unsuccessful guidewire manipulation. Methods: We retrospectively enrolled 115 patients who underwent EUS-HGS between May 2016 and April 2022 at two centers. The puncture angle between the needle and the intrahepatic bile duct was measured through EUS movie records. Results: Guidewire manipulation was unsuccessful in 28 patients. Receiver operating characteristic (ROC) curves identified an optimal puncture angle cutoff value of 85 degrees (cutoff value, 85 degrees; area under the ROC curve, 0.826; sensitivity, 85.7%; specificity, 81.6%). Multivariate analysis demonstrated that a puncture angle <85 degrees was a significant risk factor for unsuccessful guidewire manipulation (odds ratio, 19.8; 95% confidence interval, 6.42-61.5; p<0.001). Among the 28 unsuccessful cases, 24 patients (85.7%) achieved successful guidewire manipulation using various rescue methods. Conclusions: The puncture angle observed on EUS is crucial for guidewire manipulation. A puncture angle of <85 degrees was associated with unsuccessful guidewire manipulation.	[Ohno, Akihisa; Fujimori, Nao; Matsumoto, Kazuhide; Murakami, Masatoshi; Teramatsu, Katsuhito; Ueda, Keijiro; Aso, Akira; Ogawa, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3-1-1 Maidashi,Higashi Ku, Fukuoka, Fukuoka 8128582, Japan; [Ohno, Akihisa; Kaku, Toyoma; Hijioka, Masayuki] Natl Hosp Org, Clin Res Inst, Dept Gastroenterol, Kyushu Med Ctr, Fukuoka, Japan	Kyushu University	Fujimori, N (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3-1-1 Maidashi,Higashi Ku, Fukuoka, Fukuoka 8128582, Japan.	fujimori.nao.239@m.kyushu-u.ac.jp		Ohno, Akihisa/0000-0003-1372-166X; Fujimori, Nao/0000-0003-4286-8804; Ogawa, Yoshihiro/0000-0002-0834-2836; Matsumoto, Kazuhide/0000-0003-0842-6500	JSPS KAKENHI [JP18K09945]; Grant of The Clinical Research Promo-tion Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grant of The Clinical Research Promo-tion Foundation	This work was supported in part by JSPS KAKENHI (grant number: JP18K09945) and the Grant of The Clinical Research Promotion Foundation (2022) .	Artifon ELA, 2015, GASTROINTEST ENDOSC, V81, P950, DOI 10.1016/j.gie.2014.09.047; Cotton PB, 2010, GASTROINTEST ENDOSC, V71, P446, DOI 10.1016/j.gie.2009.10.027; Fugazza A, 2022, HEPATOB PANCREAT DIS, V21, P234, DOI 10.1016/j.hbpd.2022.03.003; Hara K, 2020, J HEPATO-BIL-PAN SCI, V27, P563, DOI 10.1002/jhbp.774; Isayama H, 2015, DIGEST ENDOSC, V27, P259, DOI 10.1111/den.12379; Kawakami H, 2017, ENDOSCOPY, V49, pE264, DOI 10.1055/s-0043-116014; Khan MA, 2016, DIGEST DIS SCI, V61, P684, DOI 10.1007/s10620-015-3933-0; Lee TH, 2016, CLIN GASTROENTEROL H, V14, P1011, DOI 10.1016/j.cgh.2015.12.032; Matsubara S, 2022, J CLIN MED, V11, DOI 10.3390/jcm11061591; Moole H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005154; Ogura T, 2022, GASTROINTEST ENDOSC, V96, P262, DOI 10.1016/j.gie.2022.03.013; Ogura T, 2021, ENDOSCOPY, V53, P369, DOI 10.1055/a-1199-5418; Ogura T, 2015, ENDOSCOPY, V47, pE583, DOI 10.1055/s-0034-1393381; Oh D, 2017, THER ADV GASTROENTER, V10, P42, DOI 10.1177/1756283X16671671; Ohno A, 2022, DIGEST DIS SCI, V67, P5676, DOI 10.1007/s10620-022-07555-z; Ohno A, 2022, ENDOSC ULTRASOUND, V11, P330, DOI 10.4103/EUS-D-21-00067; Sharaiha RZ, 2017, GASTROINTEST ENDOSC, V85, P904, DOI 10.1016/j.gie.2016.12.023; Uemura RS, 2018, J CLIN GASTROENTEROL, V52, P123, DOI 10.1097/MCG.0000000000000948; Ueno S, 2021, DIGEST ENDOSC, V33, pE109, DOI 10.1111/den.13993; Vila JJ, 2012, GASTROINTEST ENDOSC, V76, P1133, DOI 10.1016/j.gie.2012.08.001; Wang KX, 2016, GASTROINTEST ENDOSC, V83, P1218, DOI 10.1016/j.gie.2015.10.033	21	2	2	1	3	KOREAN SOC GASTROINTESTINAL ENDOSCOPY	SEOUL	2003 LG PALACE, 165-8 DONGGYO-DONG, MAPO-GU, SEOUL, 121-754, SOUTH KOREA	2234-2400	2234-2443		CLIN ENDOSC	Clin. Endosc.	2024 JUL 26	2024										10.5946/ce.2023.244	http://dx.doi.org/10.5946/ce.2023.244		JUL 2024	10	Gastroenterology & Hepatology	Emerging Sources Citation Index (ESCI)	Gastroenterology & Hepatology	A0G6L	39354833	Green Submitted, gold			2025-09-11	WOS:001279413900001
J	Kosaka, T; Takaori, K; Izumiya, A; Hirai, D; Koizumi, M; Yamamoto, S; Mii, A; Shimizu, A; Nakamura, K; Araki, N; Seta, K				Kosaka, Tatsuaki; Takaori, Koji; Izumiya, Azusa; Hirai, Daisuke; Koizumi, Mitsuteru; Yamamoto, Shinya; Mii, Akiko; Shimizu, Akira; Nakamura, Kiyonao; Araki, Norio; Seta, Koichi			A Case of Radiation Nephropathy Complicated by Tubulointerstitial Nephritis with Predominantly Lymphocyte and Plasma Cell Infiltration	INTERNAL MEDICINE			English	Article; Early Access						Radiation nephropathy; thrombotic microangiopathy; tubulointerstitial nephritis; contrast- enhanced computed tomography	CHEMOTHERAPY; RADIOTHERAPY	A 64-year-old Japanese woman presented with gross hematuria and was diagnosed with stage IVB cervical cancer. Renal dysfunction was observed following chemoradiation therapy, and a renal biopsy revealed renal thrombotic microangiopathy (TMA) and tubulointerstitial nephritis (TIN), which are atypical features of radiation nephropathy. Contrast-enhanced computed tomography revealed wedge-shaped areas of high contrast, consistent with areas of high radiation dose in the kidneys, thus leading to the diagnosis of radiation nephropathy. This case underscores the importance of integrating clinical, pathological, and radiological findings for the diagnosis of radiation nephropathy, atypical renal biopsy findings, and a combination of TIN and renal TMA.	[Kosaka, Tatsuaki; Takaori, Koji; Izumiya, Azusa; Hirai, Daisuke; Koizumi, Mitsuteru; Seta, Koichi] Natl Hosp Org Kyoto Med Ctr, Dept Nephrol, Kyoto, Japan; [Yamamoto, Shinya] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan; [Mii, Akiko] Nippon Med Sch, Dept Endocrinol Metab & Nephrol, Tokyo, Japan; [Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo, Japan; [Nakamura, Kiyonao] Kyoto City Hosp, Dept Radiat Oncol, Kyoto, Japan; [Araki, Norio] Natl Hosp Org Kyoto Med Ctr, Dept Radiat Oncol, Kyoto, Japan	Kyoto University; Nippon Medical School; Nippon Medical School; Kyoto City Hospital	Takaori, K (corresponding author), Natl Hosp Org Kyoto Med Ctr, Dept Nephrol, Kyoto, Japan.	kjtakaori@gmail.com		Kosaka, Tatsuaki/0000-0003-1140-3561				BERGSTEIN J, 1986, TRANSPLANTATION, V41, P63, DOI 10.1097/00007890-198601000-00013; Burton JO, 2014, KIDNEY INT, V86, P1063, DOI 10.1038/ki.2014.127; Capps GW, 1997, RADIOGRAPHICS, V17, P1455, DOI 10.1148/radiographics.17.6.9397458; Cheng JC, 2008, INT J RADIAT ONCOL, V71, P1436, DOI 10.1016/j.ijrobp.2007.12.009; Cohen EP, 2000, KIDNEY INT, V58, P903, DOI 10.1046/j.1523-1755.2000.00241.x; Cohen EP, 2003, SEMIN NEPHROL, V23, P486, DOI 10.1016/S0270-9295(03)00093-7; Cohen EP, 2003, INT J RADIAT ONCOL, V55, P190, DOI 10.1016/S0360-3016(02)03793-8; DHALIWAL RS, 1980, J PEDIATR-US, V96, P68, DOI 10.1016/S0022-3476(80)80331-3; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Ferenbach DA, 2015, NAT REV NEPHROL, V11, P264, DOI 10.1038/nrneph.2015.3; François H, 2016, NAT REV NEPHROL, V12, P82, DOI 10.1038/nrneph.2015.174; Harkenrider MM, 2015, INT J RADIAT ONCOL, V92, P921, DOI 10.1016/j.ijrobp.2015.03.010; JENNETTE JC, 1983, UROLOGY, V22, P631, DOI 10.1016/0090-4295(83)90313-8; Kala J, 2019, Journal of Onco-Nephrology, V3, P160, DOI [10.1177/2399369319865271, DOI 10.1177/2399369319865271, 10.1177/2399369319865271]; Klaus R, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01764-y; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Latcha S, 2016, CLIN J AM SOC NEPHRO, V11, P1173, DOI 10.2215/CJN.08070715; Li SP, 2023, J COSMOL ASTROPART P, DOI [10.1088/1475-7516/2023/09/009, 10.1088/1475-7516/2023/05/008]; Malyszko J, 2017, NEPHROL DIAL TRANSPL, V32, P924, DOI 10.1093/ndt/gfw338; Moinuddin I, 2015, CASE REP MED, V2015, DOI 10.1155/2015/250530; Najafian B, 2015, AM J KIDNEY DIS, V66, pE39, DOI 10.1053/j.ajkd.2015.08.009; Saeki T, 2014, KIDNEY INT, V85, P251, DOI 10.1038/ki.2013.393; Sato T, 2018, TOHOKU J EXP MED, V245, P149, DOI 10.1620/tjem.245.149; Schieda N, 2013, ACTA RADIOL OPEN, V2, DOI 10.1177/2047981613501305; Skinner HD, 2010, J GASTROINTEST ONCOL, V1, P2, DOI 10.3978/j.issn.2078-6891.2010.007; Stoffel MP, 2001, NEPHROL DIAL TRANSPL, V16, P1082, DOI 10.1093/ndt/16.5.1082; Takahashi N, 2017, J AM SOC NEPHROL, V28, P3688, DOI 10.1681/ASN.2016101074; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Yoshimura J, 2007, INTERNAL MED, V46, P1861, DOI 10.2169/internalmedicine.46.0103	29	0	1	3	3	JAPAN SOC INTERNAL MEDICINE	TOKYO	34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN	0918-2918	1349-7235		INTERNAL MED	Intern. Med.	2024 NOV 1	2024										10.2169/internalmedicine.4265-24	http://dx.doi.org/10.2169/internalmedicine.4265-24		NOV 2024	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	K9K4A	39496448	gold, Green Submitted			2025-09-11	WOS:001347011100001
J	Kubo, Y; Sone, M; Katabami, T; Izawa, S; Ichijo, T; Tsuiki, M; Okamura, S; Yoshimoto, T; Otsuki, M; Takeda, Y; Suzuki, T; Naruse, M; Tanabe, A				Kubo, Yui; Sone, Masakatsu; Katabami, Takuyuki; Izawa, Shoichiro; Ichijo, Takamasa; Tsuiki, Mika; Okamura, Shintaro; Yoshimoto, Takanobu; Otsuki, Michio; Takeda, Yoshiyu; Suzuki, Tomoko; Naruse, Mitsuhide; Tanabe, Akiyo		ACPA J Study Grp	Predictor of Steroid Replacement Duration after Removal of Cortisol-producing Adenoma	INTERNAL MEDICINE			English	Article						adrenalectomy; adrenocortical adenoma; adrenocortical hyperfunction; Cushing syndrome	CUSHINGS-SYNDROME; CURATIVE SURGERY; ADRENAL-FUNCTION; RECOVERY; TIME	Objective Cortisol-producing adenoma (CPA) is a major subtype of functional adrenal tumors. CPAs are generally treated with adrenalectomy; however, it is difficult to predict the ideal duration of glucocorticoid replacement after resection. This study explored pre-operative factors predictive of glucocorticoid replacement therapy duration after CPA resection. Mehtods This multicenter retrospective observational study was conducted as part of the Advancing Care and Pathogenesis of Intractable Adrenal Diseases in Japan (ACPA-J) from January 2006 to December 2015. Patients This study was conducted at 10 referral centers and included 124 patients who received hydrocortisone replacement therapy after adrenalectomy for CPA. Results The median duration of replacement therapy was 12 (interquartile range, 5-24) months. In the sin1-mg dexamethasone suppression test (p<0.001), presence of lumbar compression fracture (p=0.015), and Cushingoid appearance (p<0.001) were all significantly associated with the replacement therapy duration. In multiple regression analyses, the midnight serum cortisol level and presence of lumbar compression fracture were significantly correlated with the replacement therapy duration after adjusting for other parameters. Conclusion Our results suggest that high midnight serum cortisol levels, which cause persistent suppression of the hypothalamic-pituitary-adrenal axis (HPA axis), contribute to a delay in HPA axis recovery. Lumbar compression fracture is an important symptom that reflects the severity and persistence of cortisol secretion.	[Sone, Masakatsu] St Marianna Univ, Dept Metab & Endocrinol, Sch Med, Kawasaki, Japan; Kyoto Univ, Dept Diabet Endocrinol & Nutr, Kyoto, Japan; St Marianna Univ, Yokohama City Seibu Hosp, Dept Metab & Endocrinol, Kawasaki, Japan; Tottori Univ, Fac Med, Div Endocrinol & Metab, Tottori, Japan; Saiseikai Yokohama Shi Tobu Hosp, Dept Diabet & Endocrinol, Yokohama, Japan; Natl Hosp Org Kyoto MedicalCenter, Dept Endocrinol & Metab, Kyoto, Japan; Tenri Hosp, Dept Endocrinol, Tenri, Japan; Tokyo Metropolitan Hiroo Gen Hosp, Dept Diabet & Endocrinol, Tokyo, Japan; Tokyo Med & Dent Univ, Dept Mol Endocrinol & Metab, Tokyo, Japan; Tokyo Womens Med Univ, Dept Endocrinol, Tokyo, Japan; Osaka Univ, Grad Sch Med, Dept Metab Med, Osaka, Japan; Asanogawa Gen Hosp, Dept Internal Med, Kanazawa, Japan; Int Univ Hlth & Welf, Sch Med, Dept Publ Hlth, Otawara, Japan; Ijinkai Takeda Gen Hosp, Endocrine Ctr, Kyoto, Japan; Natl Ctr Global Hlth & Med, Dept Diabet Endocrinol & Metab, Tokyo, Japan	Saint Marianna University; Kyoto University; Saint Marianna University; Tottori University; Tenri Hospital; Tokyo Metropolitan Institute of Gerontology; Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU); Tokyo Women's Medical University; University of Osaka; International University of Health & Welfare; Japan Institute for Health Security (JIHS); National Center for Global Health & Medicine - Japan	Sone, M (corresponding author), St Marianna Univ, Dept Metab & Endocrinol, Sch Med, Kawasaki, Japan.	sonemasa@marianna-u.ac.jp	Izawa, Shoichiro/IXN-7454-2023		AMED, Japan [JP 17ek0109122, JP20ek0109352]; National Center for Global Health and Medicine, Japan [27-1402, 30-10081, 21A1015]; Ministry of Health, Labour, and Welfare, Japan [23FC1041]	AMED, Japan; National Center for Global Health and Medicine, Japan; Ministry of Health, Labour, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported by AMED, Japan (grant numbers JP 17ek0109122, JP20ek0109352) , the National Center for Global Health and Medicine, Japan (grant Number 27-1402, 30-10081 and 21A1015) , and a Grant-in-Aid from the Ministry of Health, Labour, and Welfare, Japan (No. 23FC1041 for research on intractable adrenal disorders) .	Barzon L, 2003, EUR J ENDOCRINOL, V149, P273, DOI 10.1530/eje.0.1490273; Berr CM, 2015, J CLIN ENDOCR METAB, V100, P1300, DOI 10.1210/jc.2014-3632; Di Dalmazi G, 2014, J CLIN ENDOCR METAB, V99, P2637, DOI 10.1210/jc.2014-1401; DOHERTY GM, 1990, SURGERY, V108, P1085; Fassnacht M, 2016, EUR J ENDOCRINOL, V175, pG1, DOI 10.1530/EJE-16-0467; GORDON D, 1987, ACTA ENDOCRINOL-COP, V114, P166, DOI 10.1530/acta.0.1140166; Hurtado MD, 2018, CLIN ENDOCRINOL, V89, P721, DOI 10.1111/cen.13803; Kim HK, 2016, ENDOCRINOL METAB, V3, P592, DOI DOI 10.3803/EnM.2016.31.4.592; KLOOS RT, 1995, ENDOCR REV, V16, P460, DOI 10.1210/er.16.4.460; Mantero F, 2000, J CLIN ENDOCR METAB, V85, P637, DOI 10.1210/jc.85.2.637; Prete A, 2017, ENDOCRINE, V55, P969, DOI 10.1007/s12020-016-1007-5; Trementino L, 2014, OSTEOPOROSIS INT, V25, P913, DOI 10.1007/s00198-013-2520-5; VALIMAKI M, 1984, CLIN ENDOCRINOL, V20, P229, DOI 10.1111/j.1365-2265.1984.tb00078.x; Yanase T, 2018, ENDOCR J, V65, P383, DOI 10.1507/endocrj.EJ17-0456	14	2	2	0	0	JAPAN SOC INTERNAL MEDICINE	TOKYO	34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN	0918-2918	1349-7235		INTERNAL MED	Intern. Med.		2024	64	10					1476	1484		10.2169/internalmedicine.4339-24	http://dx.doi.org/10.2169/internalmedicine.4339-24		OCT 2024	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3OV3M	39428528	Green Submitted, gold			2025-09-11	WOS:001337881100001
J	Mitsunaga, S; Ikeda, M; Nomura, S; Morizane, C; Todaka, A; Yamamoto, N; Kamata, K; Yanagibashi, H; Mizuno, N; Kawamoto, Y; Gotoh, K; Shirakawa, H; Okano, N; Nomura, T; Tanaka, K; Takahashi, A; Yagi, S; Ohta, K; Takayama, Y; Miwa, H; Nagano, H; Kojima, Y; Hisano, T; Tahara, M; Sakuma, Y; Arai, H; Nakamura, I; Katayama, H; Konishi, M; Ueno, M; Japan Clinical Oncology Grp JCOG HBPOG				Mitsunaga, Shuichi; Ikeda, Masafumi; Nomura, Shogo; Morizane, Chigusa; Todaka, Akiko; Yamamoto, Naoto; Kamata, Ken; Yanagibashi, Hiroo; Mizuno, Nobumasa; Kawamoto, Yasuyuki; Gotoh, Kunihito; Shirakawa, Hirofumi; Okano, Naohiro; Nomura, Tatsuya; Tanaka, Kazunari; Takahashi, Amane; Yagi, Shintaro; Ohta, Koji; Takayama, Yukiko; Miwa, Haruo; Nagano, Hiroaki; Kojima, Yasushi; Hisano, Terumasa; Tahara, Munenori; Sakuma, Yasunaru; Arai, Hiroyuki; Nakamura, Ikuo; Katayama, Hiroshi; Konishi, Masaru; Ueno, Makoto; Japan Clinical Oncology Grp JCOG HBPOG			5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1)	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						5-FU metabolic pathway; adjuvant; biliary tract cancer; DPD; S-1	DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; EXPRESSION LEVELS; MESSENGER-RNA; THYMIDINE PHOSPHORYLASE; SENSITIVITY; TUMORS; CELLS	BackgroundS-1, an oral fluoropyrimidine derivative, is standard adjuvant therapy for resected biliary tract cancer (BTC), based on the results of the JCOG1202, a phase III trial evaluating the survival benefit with adjuvant S-1 following curative resection for BTC compared to surgery alone. This multicenter ancillary study of the JCOG1202 aimed to evaluate the prognostic impact of the 5-fluorouracil (5-FU) metabolic pathway genes including thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).MethodsThe 5-FU metabolic pathway genes were measured in tumor cells from formalin-fixed paraffin-embedded resected specimens from 183 patients (surgery alone: n = 94; adjuvant S-1: n = 89). We randomly divided them into training (n = 96) and validation sets (n = 87) for evaluating the interaction between gene levels and RFS benefits in the treatment arm.ResultsRFS benefits of adjuvant S-1 were observed in the low DPD (HR = 0.440 and 0.748, respectively in the training and validation sets) and the low TP groups (HR = 0.709 and 0.602, respectively). Clinicopathological characteristics were well balanced between low and high DPD populations. More advanced stage tumors were observed in high TP populations as compared to those in low TP populations (p = .0332).ConclusionThe results suggest the RFS benefit of adjuvant S-1 in resected BTC patients with low DPD and low TP gene expressions.	[Mitsunaga, Shuichi; Ikeda, Masafumi] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan; [Mitsunaga, Shuichi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Biomarker Discovery, Kashiwa, Japan; [Nomura, Shogo; Katayama, Hiroshi] Natl Canc Ctr, JCOG Data Ctr, Operat Off, Tokyo, Japan; [Morizane, Chigusa] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan; [Todaka, Akiko] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Sunto, Japan; [Yamamoto, Naoto] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan; [Kamata, Ken] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan; [Yanagibashi, Hiroo] Chiba Canc Ctr, Dept Hepatobiliary & Pancreat Surg, Chiba, Japan; [Mizuno, Nobumasa] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Japan; [Kawamoto, Yasuyuki] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan; [Gotoh, Kunihito] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Shirakawa, Hirofumi] Tochigi Canc Ctr, Dept Hepatobiliary Pancreat Surg, Utsunomiya, Japan; [Okano, Naohiro] Kyorin Univ, Fac Med, Dept Med Oncol, Tokyo, Japan; [Nomura, Tatsuya] Niigata Canc Ctr Hosp, Dept Digest Surg, Niigata, Japan; [Tanaka, Kazunari] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan; [Takahashi, Amane] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan; [Yagi, Shintaro] Kanazawa Univ, Dept Hepatobiliary Pancreat Surg & Transplantat, Kanazawa, Japan; [Ohta, Koji] NHO Shikoku Canc Ctr, Dept Thorac Surg, Matsuyama, Japan; [Takayama, Yukiko] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, Tokyo, Japan; [Miwa, Haruo] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Japan; [Nagano, Hiroaki] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Breast & Endocrine Surg, Ube, Japan; [Kojima, Yasushi] Natl Ctr Global Hlth & Med, Dept Gastroenterol, Tokyo, Japan; [Hisano, Terumasa] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan; [Tahara, Munenori] Sapporo Kosei Gen Hosp, Dept Surg, Sapporo, Japan; [Sakuma, Yasunaru] Jichi Med Univ, Dept Surg, Shimotsuke, Japan; [Arai, Hiroyuki] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Japan; [Nakamura, Ikuo] Hyogo Med Univ, Dept Gastroenterol Surg, Kobe, Hyogo, Japan; [Konishi, Masaru] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Surg, Kashiwa, Japan; [Ueno, Makoto] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Med Oncol, Yokohama, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Shizuoka Cancer Center; Kanagawa Prefectural Cancer Center; Kindai University (Kinki University); Chiba Cancer Center; Aichi Cancer Center; Hokkaido University; Osaka National Hospital; Tochigi Prefectural Cancer Center; Kyorin University; Teine Keijinkai Hospital; Kanazawa University; Tokyo Women's Medical University; Yokohama City University; Yamaguchi University; Japan Institute for Health Security (JIHS); National Center for Global Health & Medicine - Japan; Kyushu Cancer Center; Sapporo Kosei General Hospital; Jichi Medical University; Saint Marianna University; Hyogo Medical University; National Cancer Center - Japan; Kanagawa Prefectural Cancer Center	Mitsunaga, S (corresponding author), Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	smitsuna@east.ncc.go.jp	; Morizane, Chigusa/AFV-4780-2022; Takayama, Yukiko/AAA-3070-2020; Kawamoto, Yasuyuki/GWQ-7700-2022	Kawamoto, Yasuyuki/0000-0002-7706-0015; 	Japan Agency for Medical Research and Development; Exploratory Oncology Research and Clinical Trial Center at the National Cancer Center	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Exploratory Oncology Research and Clinical Trial Center at the National Cancer Center	We sincerely appreciate the participation of the patients and their families. We thank the members of the JCOG Data Center and Operations Office for their support in overview of the study and in data management (Haruhiko Fukuda and Kyoko Hasegawa). We also thank Kayo Takei, Miho Akimoto and Yuriko Sato of the National Cancer Center Hospital East for their secretarial support, and Mariko Yajima and Michiko Hamamoto of the Exploratory Oncology Research and Clinical Trial Center at the National Cancer Center for their support with the experiment.	Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Freidlin B, 2014, NAT REV CLIN ONCOL, V11, P81, DOI 10.1038/nrclinonc.2013.218; Fukui Y, 2008, INT J MOL MED, V22, P709, DOI 10.3892/ijmm_00000076; Habara K, 2001, JPN J CANCER RES, V92, P1127, DOI 10.1111/j.1349-7006.2001.tb01068.x; Hahnvajanawong C, 2012, WORLD J GASTROENTERO, V18, P3955, DOI 10.3748/wjg.v18.i30.3955; Ishikawa Y, 1999, CLIN CANCER RES, V5, P883; Iwahashi S, 2012, SURG TODAY, V42, P565, DOI 10.1007/s00595-012-0118-8; Kim KW, 2013, MOL CLIN ONCOL, V1, P987, DOI 10.3892/mco.2013.166; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li SL, 2020, CELL BIOCHEM FUNCT, V38, P743, DOI 10.1002/cbf.3541; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morine Y, 2012, SURG TODAY, V42, P135, DOI 10.1007/s00595-011-0054-z; Nakachi K, 2023, LANCET, V401, P195, DOI 10.1016/S0140-6736(22)02038-4; Nakata B, 2004, DIGEST DIS SCI, V49, P60, DOI 10.1023/B:DDAS.0000011603.40133.f9; Naruke A, 2015, GASTRIC CANCER, V18, P262, DOI 10.1007/s10120-014-0357-z; PETERS GJ, 1986, CANCER RES, V46, P20; Sato K, 2006, INT J ONCOL, V29, P429; Shirasaka T, 1996, CANCER RES, V56, P2602; Sun XJ, 2020, PATHOL ONCOL RES, V26, P121, DOI 10.1007/s12253-018-00563-3; Thanasai J, 2010, WORLD J GASTROENTERO, V16, P1631, DOI 10.3748/wjg.v16.i13.1631; Zhang C, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/9202676	21	0	0	5	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	DEC	2024	31	12					886	896		10.1002/jhbp.12071	http://dx.doi.org/10.1002/jhbp.12071		SEP 2024	11	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	P9Z3L	39318258				2025-09-11	WOS:001381392100009
J	Nakazawa, N; Sohda, M; Hosoi, N; Watanabe, T; Kumakura, Y; Yamashita, T; Tanaka, N; Saito, K; Kimura, A; Kasuga, K; Nakazato, K; Yoshinari, D; Shimizu, H; Ubukata, Y; Hosaka, H; Sano, A; Sakai, M; Ogawa, H; Shirabe, K; Saeki, H				Nakazawa, Nobuhiro; Sohda, Makoto; Hosoi, Nobuhiro; Watanabe, Takayoshi; Kumakura, Yuji; Yamashita, Toshiki; Tanaka, Naritaka; Saito, Kana; Kimura, Akiharu; Kasuga, Kengo; Nakazato, Kenji; Yoshinari, Daisuke; Shimizu, Hisashi; Ubukata, Yasunari; Hosaka, Hisashi; Sano, Akihiko; Sakai, Makoto; Ogawa, Hiroomi; Shirabe, Ken; Saeki, Hiroshi			Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study	ONCOLOGY			English	Article						Gastric cancer; Nivolumab; Lactate dehydrogenase; Albumin; Biomarker	PROGRESSION-FREE SURVIVAL; TO-ALBUMIN RATIO; INFLAMMATORY MARKERS; SERUM-ALBUMIN; GASTRECTOMY	Introduction: In this study, we aimed to identify biomarkers for predicting treatment outcomes and efficacy of chemotherapy plus nivolumab, as well as predict immune-related adverse events (irAEs) characteristics of immune checkpoint inhibitors. Methods: This multicenter study included 104 patients who received chemotherapy plus nivolumab as the primary treatment for unresectable advanced recurrent gastric cancer. Blood test results were collected before the start and after two courses of treatment. The neutrophil-lymphocyte ratio, prognostic nutritional index, and lactate dehydrogenase/albumin ratio (LAR) were examined after treatment in each case to determine changes compared to values before the start of treatment. Results: A total of 57 (54.8%) patients experienced a complete or partial response. The LAR of the stable disease/progressive disease group significantly increased (p = 0.018). An examination of the presence of grade >= 3 irAEs and changes in related factors showed that the LAR of all patients increased. Conclusion: The LAR was correlated with the best therapeutic response; therefore, it may be a potential biomarker of treatment outcomes and efficacy.	[Nakazawa, Nobuhiro; Sohda, Makoto; Hosoi, Nobuhiro; Watanabe, Takayoshi; Sano, Akihiko; Sakai, Makoto; Ogawa, Hiroomi; Shirabe, Ken; Saeki, Hiroshi] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gunma, Japan; [Kumakura, Yuji] Tonechuo Hosp, Dept Surg, Numata, Japan; [Yamashita, Toshiki] Subaru Hlth Insurance Soc Ota Mem Hosp, Dept Surg, Ota, Japan; [Tanaka, Naritaka] Japanese Red Cross Haramachi Hosp, Dept Surg, Agatsumagun, Japan; [Saito, Kana] Gunma Cent Hosp, Dept Surg, Japan Community Healthcare Org, Maebashi, Japan; [Kimura, Akiharu] Kiryu Kosei Gen Hosp, Dept Surg, Kiryu, Japan; [Kasuga, Kengo] Isesaki City Hosp, Dept Gastroenterol, Isesaki, Japan; [Nakazato, Kenji] Fujioka Gen Hosp, Dept Surg, Fujioka, Japan; [Yoshinari, Daisuke] Natl Hosp Org Shibukawa Med Ctr, Dept Surg, Shibukawa, Japan; [Shimizu, Hisashi] Japanese Red Cross Maebashi Hosp, Dept Surg, Maebashi, Japan; [Ubukata, Yasunari] Natl Hosp Org Takasaki Gen Med Ctr, Dept Surg, Takasaki, Japan; [Hosaka, Hisashi] Gunma Prefectural Canc Ctr, Dept Gastroenterol, Ota, Japan	Gunma University; Maebashi Red Cross Hospital	Nakazawa, N (corresponding author), Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gunma, Japan.	nakazawa75@yahoo.co.jp	Shiraishi, Takuya/J-6262-2019; Shirabe, Ken/AFS-4583-2022; Nakazawa, Nobuhiro/MCK-0497-2025; Sakai, Makoto/AAW-1902-2020; Sano, Akihiko/NKP-4611-2025		JSPS KAKENHI [23K15513]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant No.23K15513).	Aday U, 2020, WSPOLCZESNA ONKOL, V24, P145, DOI 10.5114/wo.2020.100219; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fujii T, 2012, NUTR CANCER, V64, P1169, DOI 10.1080/01635581.2012.718034; Huang CM, 2022, JAMA SURG, V157, P9, DOI 10.1001/jamasurg.2021.5104; Husain B, 2021, J CANCER RES CLIN, V147, P1623, DOI 10.1007/s00432-021-03550-5; Hyung WJ, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01210; Ikeda S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3814-3; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Kang YK, 2022, LANCET ONCOL, V23, P234, DOI 10.1016/S1470-2045(21)00692-6; Kasymjanova G, 2010, CURR ONCOL, V17, P52; Kitayama J, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-47; Liu D, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1042-y; Nakazawa N, 2021, ANTICANCER RES, V41, P3925, DOI 10.21873/anticanres.15188; Obama K, 2018, GASTRIC CANCER, V21, P285, DOI 10.1007/s10120-017-0740-7; Oñate-Ocaña LF, 2007, ANN SURG ONCOL, V14, P381, DOI 10.1245/s10434-006-9093-x; Roche M, 2008, FEBS LETT, V582, P1783, DOI 10.1016/j.febslet.2008.04.057; Sano A, 2023, ANTICANCER RES, V43, P5205, DOI 10.21873/anticanres.16722; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Taniguchi Y, 2017, ANTICANCER RES, V37, P5857, DOI 10.21873/anticanres.12030; Agulló-Ortuño MT, 2020, CLIN LUNG CANCER, V21, P75, DOI 10.1016/j.cllc.2019.08.006; Tokunaga M, 2014, GASTRIC CANCER, V17, P542, DOI 10.1007/s10120-013-0293-3; Uyama I, 2019, GASTRIC CANCER, V22, P377, DOI 10.1007/s10120-018-00906-8; Yamashita K, 2011, WORLD J GASTROENTERO, V17, P3390, DOI 10.3748/wjg.v17.i29.3390	24	0	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0030-2414	1423-0232		ONCOLOGY-BASEL	Oncology	MAR	2025	103	3					201	208		10.1159/000540841	http://dx.doi.org/10.1159/000540841		SEP 2024	8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	Z6L6T	39447553				2025-09-11	WOS:001329232200001
J	Nakazawa, N; Sano, A; Kumakura, Y; Yamashita, T; Tanaka, N; Saito, K; Kimura, A; Kasuga, K; Nakazato, K; Yoshinari, D; Shimizu, H; Ubukata, Y; Hosaka, H; Shiraishi, T; Sakai, M; Sohda, M; Shirabe, K; Saeki, H				Nakazawa, Nobuhiro; Sano, Akihiko; Kumakura, Yuji; Yamashita, Toshiki; Tanaka, Naritaka; Saito, Kana; Kimura, Akiharu; Kasuga, Kengo; Nakazato, Kenji; Yoshinari, Daisuke; Shimizu, Hisashi; Ubukata, Yasunari; Hosaka, Hisashi; Shiraishi, Takuya; Sakai, Makoto; Sohda, Makoto; Shirabe, Ken; Saeki, Hiroshi			Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study	ONCOLOGY			English	Article						Gastric cancer; Nivolumab; Prognostic nutrition index; Treatment sensitivity; Biomarker		Introduction: This multicenter study aimed to determine whether the pretreatment prognostic nutrition index (PNI) or a change in the index after two treatment courses could be a biomarker for predicting treatment sensitivity in patients with unresectable advanced or recurrent gastric cancer treated using chemotherapy and nivolumab as the first-line treatment. Methods: This multicenter retrospective study with 104 patients was conducted at 12 institutions. PNI was calculated before treatment and after two courses of treatment in each case. We also focused on changes in PNI from the pretreatment value. Results: After two courses of chemotherapy plus nivolumab treatment, the high PNI group had significantly better rates of overall survival (OS) (p = 0.0016) and time-to-treatment failure (p = 0.0060). Low PNI was an independent prognostic factor predicting both therapeutic sensitivity to chemotherapy plus nivolumab treatment and poorer OS. Furthermore, correlation with low pretreatment PNI transitioning to high after two courses of treatment was not noted in any patient in the progressive disease group (p = 0.0075). Conclusions: PNI is a score composed of a patient's albumin level and lymphocyte count that can be easily assessed in daily clinical practice. Evaluating it is easy for each treatment; thus, when there is a focus on its transition, PNI could be a very powerful biomarker for predicting treatment sensitivity.	[Nakazawa, Nobuhiro; Sano, Akihiko; Shiraishi, Takuya; Sakai, Makoto; Sohda, Makoto; Shirabe, Ken; Saeki, Hiroshi] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Japan; [Kumakura, Yuji] Tonechuo Hosp, Dept Surg, Numata, Japan; [Yamashita, Toshiki] Ota Mem Hosp, Subaru Hlth Insurance Soc, Dept Surg, Ota, Japan; [Tanaka, Naritaka] Japanese Red Cross Haramachi Hosp, Dept Surg, Agatsumagun, Japan; [Saito, Kana] Japan Community Healthcare Org Gunma Cent Hosp, Dept Surg, Maebashi, Japan; [Kimura, Akiharu] Kiryu Kosei Gen Hosp, Dept Surg, Kiryu, Gumma 3760024, Japan; [Kasuga, Kengo] Isesaki City Hosp, Dept Gastroenterol, Isesaki, Japan; [Nakazato, Kenji] Fujioka Gen Hosp, Dept Surg, Fujioka, Japan; [Yoshinari, Daisuke] Natl Hosp Org Shibukawa Med Ctr, Dept Surg, Shibukawa, Japan; [Shimizu, Hisashi] Japanese Red Cross Maebashi Hosp, Dept Surg, Maebashi, Japan; [Ubukata, Yasunari] Natl Hosp Org Takasaki Gen Med Ctr, Dept Surg, Takasaki, Gunma, Japan; [Hosaka, Hisashi] Gunma Prefectural Canc Ctr, Dept Gastroenterol, Ota, Gunma, Japan	Gunma University; Maebashi Red Cross Hospital	Sano, A (corresponding author), Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Japan.	ak_sano@gunma-u.ac.jp	Shiraishi, Takuya/J-6262-2019; Shirabe, Ken/AFS-4583-2022; Nakazawa, Nobuhiro/MCK-0497-2025; Sakai, Makoto/AAW-1902-2020; Sano, Akihiko/NKP-4611-2025		JSPS KAKENHI [23K15513]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant No. 23K15513).	CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; FLECK A, 1985, LANCET, V1, P781; Galdiero MR, 2013, J CELL PHYSIOL, V228, P1404, DOI 10.1002/jcp.24260; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Kang YK, 2022, LANCET ONCOL, V23, P234, DOI 10.1016/S1470-2045(21)00692-6; Kitayama J, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-47; Korkmaz M, 2023, J GASTROINTEST CANC, V54, P962, DOI 10.1007/s12029-023-00972-x; Liu D, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1042-y; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Migita K, 2017, SURG TODAY, V47, P1018, DOI 10.1007/s00595-017-1469-y; Okubo K, 2021, ONCOLOGY-BASEL, V99, P380, DOI 10.1159/000514572; Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001; Pan YT, 2023, NUTRIENTS, V15, DOI 10.3390/nu15194290; Roche M, 2008, FEBS LETT, V582, P1783, DOI 10.1016/j.febslet.2008.04.057; Sasaki T, 2022, INT J CLIN ONCOL, V27, P948, DOI 10.1007/s10147-022-02131-x; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Xiao H, 2020, EUR J CLIN NUTR, V74, P555, DOI 10.1038/s41430-019-0502-1; Zhang LL, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1219929; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	22	0	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0030-2414	1423-0232		ONCOLOGY-BASEL	Oncology	MAY	2025	103	6					469	476		10.1159/000541544	http://dx.doi.org/10.1159/000541544		OCT 2024	8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	3SW6P	39447553				2025-09-11	WOS:001354587500001
